



PDM Persatuan
Dermatologi
Malaysia
Dermatological Society of Malaysia
• Since 1974



PDM

Annual General Meeting & Annual Dermatology Conference 2025

**Dermatology - Remember
the Past, Embrace the Present
and Rise to the Future**

4th to 7th September 2025

**Connexion Conference & Event Centre (Nexus)
Kuala Lumpur, Malaysia**

www.dermatology.org.my

SOUVENIR PROGRAMME



IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN'T YOU?¹

Indications

SHINGRIX is indicated for the prevention of **herpes zoster (HZ)** and **post-herpetic neuralgia (PHN)** in



Adults aged **50 years or older¹**



Adults **18 years or older** at increased risk of HZ¹



SHINGRIX offers **97% efficacy** for adults ≥ 50 years of age. SHINGRIX offers **91% efficacy** for adults ≥ 70 years of age.^{1*}



MSIDC and CDC recommend vaccinating adults ≥ 50 years with **2 doses of SHINGRIX**.^{2,3}

The 2nd dose should be administered **2 months after the 1st dose**. (flexible, between 2 – 6 months if necessary).

Shingrix Safety Information¹

- ▶ Hypersensitivity to the active substances or to any component of the vaccine.
- ▶ Very common adverse events include headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and / or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.

Median follow-up period of 3.1-4 years in ZOE-50/70.¹

* 97.2% (95% CI: 93.7; 99.0) VE against confirmed shingles in subjects ≥ 50 years in ZOE-50, 91.3 (95% CI: 86.8; 94.5) VE against confirmed shingles in subjects ≥ 70 years in pooled data from ZOE-50 and ZOE-70.¹

References: 1. Shingrix Prescribing Information. 2. Centers for Disease Control and Prevention. Shingles vaccination. Reviewed May 8, 2023. Accessed May 8, 2024. <https://www.cdc.gov/vaccines/vpd/shingles/public/Shingrix/index.html>. 3. Guideline for Adult Immunization - 3rd Edition, Malaysia Society of Infectious Diseases and Chemotherapy (Published in October 2020, Revised in November 2023), Page 187.

For Malaysia Healthcare Professionals Only

This educational program is sponsored by GSK.

Adverse events should be reported to drugsafetyinfo.my@gsk.com

Trade marks are owned by or licensed to the GSK group of companies.

© 2025 GSK group of companies or its licensor.

GlaxoSmithKline Pharmaceutical Sdn Bhd 195801000141 (3277-U)

HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama, Bandar

Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia.

Tel: (603) 2037 9808 www.my.gsk.com

Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code.

For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at medinfo.my@gsk.com.



CONTENTS

Welcome Message from the President	2
Executive Committee 2024 - 2026	3
Organising Committee	4
Faculty	5 - 8
Programme Summary	9
Daily Programme	
• 4 th September 2025 (Thursday)	10
• 5 th September 2025 (Friday)	11 - 13
• 6 th September 2025 (Saturday)	14 - 15
• 7 th September 2025 (Sunday)	16
Lectures & Symposia	19 - 38
Oral Presentations	39 - 40
Poster Presentations	41 - 48
Trade Exhibition	50 - 52
Acknowledgements	53 - 54

WELCOME MESSAGE



Distinguished Guests, Esteemed Speakers, Colleagues, and Friends,

It is with great pride and immense joy that I welcome all of you to the **50th Golden Jubilee Annual General Meeting and Annual Dermatology Conference 2025** of the **Persatuan Dermatologi Malaysia**, taking place from **4th to 7th September 2025** at the **Connexion Conference & Event Centre (Nexus), Bangsar South, Kuala Lumpur**.

This year, we celebrate not only another successful annual conference but also a truly significant milestone - **50 glorious years since the inception of PDM**. It is a time for reflection, celebration and anticipation of the future.

Our conference theme, ***“Remember the Past, Embrace the Present, and Rise to the Future”*** perfectly encapsulates the spirit of this Golden Jubilee. From our humble beginnings with just a handful of dedicated dermatologists, PDM has grown into a strong and respected professional body with over 230 members. Together, we have built a dynamic dermatological community that continues to serve the nation with dedication, scientific rigour and compassion.

This year's programme reflects our shared commitment to clinical excellence and professional advancement. The Scientific Committee has curated an outstanding line-up of local and international faculty, covering groundbreaking topics across both medical and cosmetic dermatology. The sessions are designed not only to update us on the latest technological advancements but also to sharpen our competencies and refine our skills in managing complex, challenging, and chronic skin conditions. The conference also offers invaluable opportunities to engage with leading experts from the region.

One of the major highlights will be the **official launch of the updated Malaysia Clinical Practice Guidelines on the Management of Psoriasis**. This updated CPG reflects our collective efforts to deliver evidence-based, patient-centred care for individuals living with psoriasis - a condition that impacts not only the skin but also overall quality of life.

This Golden Jubilee is the perfect opportunity for our fraternity to come together in fellowship, and to reminisce about the cherished moments and milestones we share as part of PDM. As part of this special celebration, we have prepared a **commemorative coffee table book** and meaningful souvenirs to mark the occasion. We warmly invite you to join us for the **PDM Annual Gala Dinner on 6th September 2025**.

We also encourage you to explore the trade booths at the biomedical industry exhibition, where you can discover innovative medications and advanced technologies that will enhance our ability to deliver holistic patient care.

Thank you, and Happy 50th Anniversary to PDM!

I look forward to welcoming you all in Kuala Lumpur.

A handwritten signature in black ink, appearing to read 'Tan Wooi Chiang'.

Associate Professor Dr Tan Wooi Chiang
President
Persatuan Dermatologi Malaysia 2024-2026 &
Organising Chair, PDM AGM & ADC 2025

EXECUTIVE COMMITTEE 2024 – 2026

President

Associate Professor Dr Tan Wooi Chiang

Vice President

Dr Peter Ch'ng Wee Beng

Immediate Past President

Dr Sabeera Begum

Honorary Secretary

Dr Sharifah Rosniza Syed Nong Chek

Honorary Treasurer

Dr Benji Teoh Tze Yuen

Executive Committee Members

Dr How Kang Nien

Dr Teeba Raja

Dr Nirmala Ponnuthurai

Dr Zareen Aidah Yahya

ORGANISING COMMITTEE

Organising Chairperson

Associate Professor Dr Tan Wooi Chiang

Scientific Chairperson

Dr Sharifah Rosniza Syed Nong Chek

Scientific Co-Chair

Dr Tang Min Moon

Honorary Secretary

Dr Sharifah Rosniza Syed Nong Chek

Honorary Treasurer

Dr Benji Teoh Tze Yuen

Social Event

Dr Peter Ch'ng Wee Beng

Dr Teeba Raja

Abstract

Dr How Kang Nien

Dr Zareen Aidah Yahya

Pre-Conference Workshop

Dr Sabeera Begum

Dr Nirmala Ponnuthurai

INTERNATIONAL FACULTY



Richard John Barlow
Consultant Dermatologist
St John's Institute of Dermatology
United Kingdom



Pan Jiun Yit
Senior Consultant Dermatologist
National Skin Centre
Singapore



Chai Zi Teng
Consultant Dermatologist
Singapore General Hospital
Singapore



Annika Smith
Consultant Dermatologist
St Vincent's Private Hospital
Australia



Adelaide Ann Hebert
Consultant Paediatric Dermatologist
The University of Texas Medical
School
United States



Thanya Techapichetvanich
Consultant Dermatologist
Faculty of Medicine Siriraj Hospital,
Mahidol University
Bangkok
Thailand



Kok Wai Leong
Consultant Dermatologist
HMI Medical Centre
Singapore



Colin Theng Thiam Seng
Senior Consultant Dermatologist and
Founder
The Skin Specialists and Laser Clinic
Singapore



Linda Martin
Senior Consultant Dermatologist
University of New South Wales and
Melanoma Institute Australia
Australia



Rungsima Wanitphakdeedecha
Consultant Dermatologist
Faculty of Medicine Siriraj Hospital,
Mahidol University
Bangkok
Thailand



Mok Zhun Rui
Consultant Dermatologist
The Dermatology Practice and
Gleneagles Hospital
Singapore

LOCAL FACULTY



Azura Mohd Affandi

Consultant Dermatologist
Hospital Kuala Lumpur
Kuala Lumpur
Malaysia



Hanaliza Isa

Senior Assistant Director
Tax Operational Sector
Inland Revenue Board of Malaysia
Selangor
Malaysia



Ch'ng Chin Chwen

Consultant Dermatologist
Subang Jaya Medical Centre
Selangor
Malaysia



Harikannan Ragavan

Founding and Managing Partner
Jayadeep, Hari and Jamil (JHJ)
Kuala Lumpur
Malaysia



Peter Ch'ng Wee Beng

Consultant Dermatologist
Gleneagles Hospital Kuala Lumpur
Kuala Lumpur
Malaysia



Henrietta Albela

Consultant Paediatric Dermatologist
Sarawak General Hospital
Sarawak
Malaysia



Chang Choong Chor

Consultant Dermatologist
Gleneagles Hospital Kuala Lumpur
Kuala Lumpur
Malaysia



How Kang Nien

Consultant Dermatologist
Hospital Sultan Abdul Aziz Shah, UPM
Selangor
Malaysia



Steven Chow Kim Weng

Senior Consultant Dermatologist
Pantai Hospital Kuala Lumpur
Kuala Lumpur
Malaysia



Jeyakantha Ratnasingam

Senior Consultant Endocrinologist
and the Head of Endocrinology
Universiti Malaya Medical Centre
Kuala Lumpur
Malaysia



Henry Foong Boon Bee

Consultant Dermatologist
Foong Skin Specialist Clinic
Ipoh, Perak
Malaysia



Kaema Nadarajan a/p Nadarajan

Country Manager in Malaysia for MPS
Medical Protection Society
Malaysia

LOCAL FACULTY



Kwan Zhenli

Consultant Dermatologist
Subang Jaya Medical Centre
Selangor
Malaysia



Sharmini a/p Ganasegaran

Assistant Vice President at Lockton
Consulting
Medical Protection Society
Malaysia



Lai Oi Ming

Profesor
Faculty of Biotechnology and
Biomolecular Sciences
Universiti Putra Malaysia
Selangor
Malaysia



Tan Kit Mun

Senior Consultant Geriatrician
Universiti Malaya Medical Centre
Kuala Lumpur
Malaysia



Leong Kin Fon

Consultant Dermatologist
Tunku Azizah Hospital
Kuala Lumpur
Malaysia



Tang Jyh Jong

Consultant Dermatologist and Head
Hospital Raja Permaisuri Bainun
Ipoh, Perak
Malaysia



Low Dy-Win

Consultant Dermatologist
Sunway Medical Center Penang
Penang
Malaysia




Tang Min Moon

Consultant Dermatologist and
Head of Department
Hospital Umum Sarawak
Sarawak
Malaysia



Nur Aileen Wee Abdullah

Growell Baby and Child Specialist
Clinic (Ampang)
Selangor
Malaysia



Melinda Tong Mui Leng

Specialist Skin Clinic
Sabah
Malaysia



Rajalingam Ramalingam

Head of Dermatology
Hospital Tengku Ampuan Afzan
Kuantan, Pahang
Malaysia



Teeba Raja

Consultant Dermatologist
Hospital Selayang
Selangor
Malaysia

LOCAL FACULTY



Michelle Voo Sook Yee
Consultant Dermatologist
Hospital Queen Elizabeth
Sabah
Malaysia



Evelyn Yap Wen Yee
Consultant Dermatologist
Mahkota Medical Centre
Melaka
Malaysia



Felix Yap Boon Bin
Consultant Dermatologist
Sunway Medical Centre
Selangor
Malaysia



Yong Shin Shen
Consultant Dermatologist
Universiti Malaya Medical Centre
Kuala Lumpur
Malaysia

PROGRAMME SUMMARY

Date Time	4 th September 2025 (Thursday)		5 th September 2025 (Friday)		6 th September 2025 (Saturday)		7 th September 2025 (Sunday)			
0730 - 0800	Registration									
0800 - 0830	MALAYSIA PSORIASIS REGISTRY MEETING		SYMPOSIA 11		FREE PAPER PRESENTATIONS 12		CONTROVERSIES			
23										
0830 - 0900			GOVERNMENT DERMATOLOGIST MEETING		MORNING FOCUS 14		MORNING FOCUS 25		DIALOGUE WITH LIAM (Or Derm Dialogue/Controversies)	
0900 - 0930	Opening Ceremony & Psoriasis CPG Launching				MORNING FOCUS 36		MORNING FOCUS 47		MORNING FOCUS 58	
0930 - 1000					Coffee Break					
1000 - 1030	Trade Exhibition Opening / Booth Visit / Coffee Break				PLENARY LECTURE 29		PLENARY LECTURE 310			
1030 - 1100	PLENARY LECTURE 111				SYMPOSIA 912		SYMPOSIUM 1113			
1100 - 1130					914		1015			
1130 - 1200					1216		1317			
1200 - 1230	Lunch		PRE-LUNCH SYMPOSIUM 118		PRE-LUNCH SYMPOSIUM 219		PRE-LUNCH SYMPOSIUM 320			
1230 - 1300			LUNCH SYMPOSIA 121		LUNCH SYMPOSIA 132		LUNCH SYMPOSIUM 524			
1300 - 1330	PDM SUB- COMMITTEE MEETING		Dermatopathology CPC		125		226			
SYMPOSIA 327					CLOSING CEREMONY & BOOTH PASSPORT DRAW					
1330 - 1400							428			
1400 - 1430			EVENING FOCUS 129		EVENING FOCUS 230		PDM Annual General Meeting			
1430 - 1500			Coffee Break							
1500 - 1530			SYMPOSIA 531		632					
1530 - 1600										
1600 - 1630			FACULTY DINNER (by invitation only)				PDM Annual Gala Dinner			
1630 - 1700										
1700 - 1830										
1830 - 1900										
1900 - 2030										
2030 - 2200										

DAILY PROGRAMME

4th September 2025 (Thursday)

0800 - 0830 Registration

0830 - 0930 **MALAYSIA PSORIASIS REGISTRY**

0930 - 1230 **GOVERNMENT DERMATOLOGIST MEETING**

1230 - 1400 Lunch

<p>1400 - 1500 <i>Venue: Spectrum, CCEC</i></p> <p>PDM SUB-COMMITTEE MEETING</p>	<p>1400 - 1500 <i>Venue: Tunku Azizah Hospital</i></p> <p>Dermatopathology CPC</p> <p>Presentation and Sharing of Interesting Cases</p> <p><i>Panelists: Dawn Ambrose / Lee Bang Rom / Zuliatul Faizah / Ikmal Hisyam Bakrin / Moonyza Akmal Ahmad Kamil</i></p>
--	--

DAILY PROGRAMME

5th September 2025 (Friday)

0730 - 0800 Registration

Venue: Nexus 1	Venue: Spectrum
<p>0800 - 0930 SYMPOSIUM 1 Hot Topics That Matters Chairpersons: <i>Sabeera Begum</i> E-Invoicing for Doctors <i>Hanaliza Isa</i></p> <p>The Importance of Medical Indemnity: Protecting Doctors When Things Go Wrong <i>Kaema Nadarajan a/p Nadarajan</i> <i>Sharmini a/p Ganasegaran</i></p> <p>Expert Witness and The Courts <i>Harikannan Ragavan</i></p> <p>0930 - 1000 MORNING FOCUS 1 (Hyphens) Chairperson: <i>Nik Aimee Azizah Faheem</i> Beyond the Surface: Optimizing Hand Eczema Management Through Skin pH Control and Barrier Support <i>Ch'ng Chin Chwen</i></p>	<p>0800 - 0930 SYMPOSIUM 2 Paediatric Dermatology Chairperson: <i>Nirmala Ponnuthurai / Nur Aileen Wee Abdullah</i> Paediatric Contact Dermatitis: What is Important? <i>Nur Aileen Wee Abdullah</i></p> <p>Anogenital Skin Diseases in Children and Adolescents <i>Henrietta Albela</i></p> <p>Use of JAK Inhibitor in Paediatric Dermatology <i>Leong Kin Fon</i></p> <p>0930 - 1000 MORNING FOCUS 2 (Zuellig) Chairperson: <i>Nur Syazwin Sies</i> From Flares to Freedom: A New Era in Pediatric AD Treatment with Baricitinib <i>Leong Kin Fon</i></p>
<p>1000 - 1115 Opening Ceremony & Psoriasis CPG Launching</p> <p>Negaraku Doa recitation</p> <p>Welcome Speech by President of Dermatological Society of Malaysia <i>Tan Wooi Chiang</i></p> <p>Overview of the CPG Management of Psoriasis (Second Edition) by Chairman of CPG <i>Tang Jyh Jong</i></p> <p>Launching Speech by Pengarah Bahagian Perkembangan Perubatan, Kementerian Kesihatan Malaysia <i>Mohd Azman Yacob</i></p> <p>Launching of CPG</p> <p>Presentation of CPG Packages to Representatives of Director of State Health Department, Dean of Medical Faculties, President of Societies</p> <p>Group Photo Session</p>	

DAILY PROGRAMME

5th September 2025 (Friday)

1115 - 1145 Trade Exhibition Opening / Booth Visit / Coffee Break

1145 - 1230 **PLENARY LECTURE 1**

Chairperson: Peter Ch'ng Wee Beng

Ganesapillai Memorial Lecture - The PDM Journey

Steven Chow Kim Weng

Nexus 1

Venue: Nexus 1	Venue: Spectrum
<p>1230 - 1300 PRE-LUNCH SYMPOSIUM 1 (Glenmark) Expanding Horizons: Emerging Roles of Apremilast in Psoriasis Management <i>Low Dy-Win</i></p> <p>1300 - 1400 LUNCH SYMPOSIUM 1 (Galderma) <i>Chairpersons: Azura Mohd Affandi / Kwan Zhenli</i> Trifarotene: A Breakthrough in Acne Care - Real-World Insights <i>Azura Mohd Affandi</i></p> <p>Role of Dermocosmetic in Sensitive Skin Focusing on the Role of Moisturisers <i>Kwan Zhenli</i></p> <p>1400 - 1500 SYMPOSIUM 3 <i>Important Laboratory Supports in Dermatology</i> <i>Chairpersons: Zareen Yahya / Tang Ming Moon</i> Laboratory Diagnostic Work Up for Genodermatoses: What is Important? <i>Leong Kin Fon</i></p> <p>Important PCR Tests in Dermatology <i>Tang Min Moon</i></p> <p>Lab Tests for "Allergy": How to Interpret? <i>Chai Zi Teng</i></p> <p>1500 - 1530 EVENING FOCUS 1 (Novartis) <i>Chairperson: Tan Wooi Chiang</i> SECuring Window of opportunity in Psoriasis <i>Colin Theng Thiam Seng</i></p>	<p>1230 - 1300 PRE-LUNCH SYMPOSIUM 2 (J&J) <i>Chairperson: Tang Jyh Jong</i> Pioneering Lasting Skin Clearance and Memory Reset in Psoriasis with Guselkumab <i>Annika Smith</i></p> <p>1300 - 1400 LUNCH SYMPOSIUM 2 (GSK) <i>Chairperson: How Kang Nien</i> Shingles: Beyond The Rash - Empowering Physicians in Prevention <i>Tan Kit Mun</i></p> <p>1400 - 1500 SYMPOSIUM 4 <i>Sensitive Skin and Scars</i> <i>Chairpersons: Teeba Raja / Henry Foong Boon Bee</i> From Lasers to Injectables: Strategic Integration in Acne Scar Management <i>Thanya Techapichetvanich</i></p> <p>Surgical Management of Keloids and Hypertrophic Scar <i>Richard John Barlow</i></p> <p>Sensitive Skin Syndrome: Current Understanding <i>Ch'ng Chin Chwen</i></p> <p>1500 - 1530 EVENING FOCUS 2 (Loreal) Breakthroughs in Hyperpigmentation & Photoprotection <i>Kok Wai Leong</i></p>
1530 - 1600 Coffee Break	

DAILY PROGRAMME

5th September 2025 (Friday)

Venue: Nexus 1	Venue: Spectrum
<p>1600 - 1700 SYMPOSIUM 5 <i>Nasty Infections in Dermatology</i> <i>Chairpersons: Sharifah Rosniza Syed Nong Chek / Suganthi Robinson</i></p> <p>Recalcitrant Non-genital Cutaneous Warts: A Review of The Treatment Options <i>Pan Jiun Yit</i></p> <p>Treatment-Resistant Leprosy: How to Manage? <i>Rajalingam Ramalingam</i></p> <p>The Alarming Recalcitrant Dermatophytosis <i>Pan Jiun Yit</i></p>	<p>1600 - 1700 SYMPOSIUM 6 <i>Risk Management in Dermato-Surgical Procedures</i> <i>Chairpersons: How Kang Nien / Kwan Zhenli</i></p> <p>Preventing and Managing Complications in Dermatologic Surgery <i>Richard John Barlow</i></p> <p>Risks of Fillers in Dermatology: How to Manage Them? <i>Thanya Techapichetvanich</i></p> <p>Minimizing Complications of Laser Treatment in Skin of Colours <i>Henry Foong Boon Bee</i></p>
1830	FACULTY DINNER (by invitation only)

DAILY PROGRAMME

6th September 2025 (Saturday)

0730 - 0800 Registration

Venue: Nexus 1	Venue: Spectrum
<p>0800 - 0900 FREE PAPER PRESENTATION 1</p> <p>0900 - 1000 SYMPOSIUM 7 <i>Targeted Therapies and The Associated Dermatological Adverse Events - What Do We Do?</i> <i>Chairperson: Sharifah Rosniza Syed Nong Chek</i> Cutaneous Toxicity of EGFR Inhibitors <i>Tang Min Moon</i></p> <p>Dermatological Adverse Events of Immune Checkpoint Inhibitors <i>Chai Zi Teng</i></p> <p>Adverse Events of Special Interests From Common Biologics & Small Molecules Used in Dermatology <i>Felix Yap Boon Bin</i></p> <p>1000 - 1030 MORNING FOCUS 3 (Zuellig) <i>Chairperson: Peter Ch'ng Wee Beng</i> Talk of the Town: The TIME for GIP IS NOW <i>Jeyakantha Ratnasingam</i></p>	<p>0800 - 0900 FREE PAPER PRESENTATION 2</p> <p>0900 - 1000 SYMPOSIUM 8 <i>All about Aging</i> <i>Chairperson: Noor Zalmy Azizan</i> Topical Pharmacological Agents with Antiaging Properties <i>How Kang Nien</i></p> <p>Photoprotection and Systemic Antioxidants <i>Teeba Raja</i></p> <p>What is New in Managing Androgenetic Alopecia <i>Sean Yong Shin Shen</i></p> <p>1000 - 1030 MORNING FOCUS 4 (Boehringer Ingelheim) <i>Chairperson: Chang Choong Chor</i> Breaking the Flare Cycle: Malaysia's First Real-World Experience with spesolimab in Generalized Pustular Psoriasis <i>Peter Ch'ng Wee Beng</i></p>
<p>1030 - 1100 Coffee Break</p> <p>1100 - 1130 PLENARY LECTURE 2 <i>Malcolm Greaves Memorial Lecture</i> <i>Chairperson: Tan Wooi Chiang</i> Melanoma in Skin of Colour <i>Linda Martin</i></p>	<p style="text-align: right;">Nexus 1</p>
<p>1130 - 1230 SYMPOSIUM 9 <i>Pigmentary Disorders</i> <i>Chairpersons: How Kang Nien / Tang Jyh Jong</i> Novel Treatment in Vitiligo <i>Tang Jyh Jong</i></p> <p>Cosmeceuticals for Melasma <i>Felix Yap Boon Bin</i></p> <p>Pigmented Nails in Skin of Color: How to Approach? <i>Sean Yong Shin Shen</i></p>	<p>1130 - 1230 SYMPOSIUM 10 <i>Toxins</i> <i>Chairpersons: Peter Ch'ng Wee Beng / Nur Ashikin Ahmad</i> Optimising Facial Botulinum Toxin Results <i>Melinda Tong Mui Leng</i></p> <p>Non-Cosmetic Dermatological Use of Botulinum Toxin <i>Teeba Raja</i></p> <p>Botulinum Toxins: Risks and Safety <i>Peter Ch'ng Wee Beng</i></p>

DAILY PROGRAMME

6th September 2025 (Saturday)

Venue: Nexus 1		Venue: Spectrum
1230 - 1300 PRE-LUNCH SYMPOSIUM 3 (Ranbaxy) <i>Chairperson: Pubalan Muniandy</i> Tildrakizumab: Illuminating New Horizons in Psoriasis Care <i>Felix Yap Boon Bin</i>		1230 - 1300 PRE-LUNCH SYMPOSIUM 4 (Menarini) <i>Chairperson: Tang Jyh Jong</i> Beyond the Hives: Elevating Patient Care in Chronic Urticaria <i>Azura Mohd Affandi</i>
1300 - 1400 LUNCH SYMPOSIUM 3 (Loreal) Restoring the Epidermal Barrier: Why Skin Identical Ceramides Matter <i>Mok Zhun Rui / Evelyn Yap Wen Yee</i>		1300 - 1400 LUNCH SYMPOSIUM 4 (Pfizer) Advancing the Paradigm: JAK Inhibition in Atopic Dermatitis and Alopecia Areata <i>Adelaide Hebert</i>
1430 - 1630	PDM Annual General Meeting	<i>Spectrum</i>
1900 - 2200	PDM Annual Gala Dinner	<i>Nexus 1</i>

DAILY PROGRAMME


7th September 2025 (Sunday)

Venue: Nexus 1

0730 - 0800	Registration
0800 - 0900	<p>CONTROVERSIES</p> <p><i>Chairpersons: Benji Teoh Tze Yuen / Chang Choong Chor</i></p> <p>Patch Testing Prior to Metal Implants: Is it Necessary? <i>Michelle Voo Sook Yee</i></p> <p>Augmented Reality Technology in Aesthetic Dermatology <i>Rungsima Wanitphakdeedecha</i></p> <p>Topical Steroid Withdrawal Syndrome: Should we Worry? <i>Chang Choong Chor</i></p>
0900 - 1000	<p>DIALOGUE WITH LIAM</p> <p><i>Chairperson: Benji Teoh Tze Yuen</i></p> <p><i>Chooi Joo Lee</i></p>
1000 - 1030	<p>MORNING FOCUS 5 (Eucerin)</p> <p><i>Chairperson: How Kang Nien</i></p> <p>Groundbreaking Anti-Aging with Epigenetic Innovation: Latest Update in ASEAN Study <i>Rungsima Wanitphakdeedecha</i></p>
1030 - 1100	Coffee Break
1100 - 1130	<p>PLENARY LECTURE 3</p> <p><i>Chairperson: Tan Wooi Chiang</i></p> <p>Fillers in Dermatology: The Past, The Present and The Future <i>Rungsima Wanitphakdeedecha</i></p>
1130 - 1230	<p>SYMPOSIUM 11 Dermato-Oncology</p> <p><i>Chairpersons: Teeba Raja</i></p> <p>The Unusual Presentations of Malignant Melanoma <i>Linda Martin</i></p> <p>Approach to BCC <i>Kwan Zhenli</i></p> <p>Clinical Decision Making in Malignant Melanoma: How to Treat in 2025? <i>Linda Martin</i></p>
1230 - 1300	<p>PRE-LUNCH SYMPOSIUM 5 (Lipidgroup)</p> <p>Tocotrienol-Rich Moisturiser and Inflamed Skin Conditions <i>Lai Oi Ming</i></p>
1300 - 1400	<p>LUNCH SYMPOSIUM 5 (Sanofi)</p> <p>Beyond the Surface: Leveraging Subclinical Biomarkers Like TARC to Personalize Atopic Dermatitis Treatment <i>Evelyn Yap Wen Yee</i></p>
1400 - 1430	CLOSING CEREMONY & BOOTH PASSPORT DRAW

ANTHELIOS ANTI-DARK SPOTS FLUID

NEW



**ULTRA-LONG UVA
PROTECTION AGAINST:
INDUCED PIGMENTATION¹
& DNA DAMAGE²**

**PROTECT
MEXORYL 400**



**HYPERPIGMENTATION
CORRECTION:
ON ALL PHOTOTYPES³⁻⁵**

**CORRECT
MELASYL™**

**TRAPS MELANIN PRECURSORS:
DHI, DHICA, DOPAQUINONE**

NOW POWERED BY MELASYL™

1. Clinical study conducted on 5 subjects with normal skin. Application of UVMune OIL CONTROL and main competitor, before exposure to Increased dose of LONG UVA (370nm to 400nm) at 50, 65 and 81 J/cm². Pigmentation assessed by clinical scoring and visualization with MEDcam camera. Data shown for best case.
2. Marionnet C, de Dormael R, Marat X, Roudot A, Gizard J, Planel E, Tornier C, Goleblewski C, Bastien P, Candau D, Bernerd F. Sunscreens with the New MCE Filter Cover the Whole UV Spectrum: Improved UVA1 Photoprotection In-Vitro and in a Randomized Controlled Trial. JID Innov. 2021 Nov 25;2(1):100070. doi: 10.1016/j.xjidi.2021.100070. PMID: 35072138; PMCID: PMC8762479.
3. Open-label study: 3 months before-and-after interventional study, phototypes II-VI, single-center on 17 patients with acne induced PIH.
4. Open-label study: 3 months before-and-after interventional study, single-center, phototypes II-VI, on 24 patients with mild to moderate melasma.
5. Complete study: 6 months randomized control study, 109 patients, phototype I-IV, with all severity (mild, moderate, severe) epidermal or mixed melasma.

Distributed by:
APEX PHARMACY MARKETING SDN BHD
No. 2, Jalan SS13/15, 47500 Subang Jaya
Selangor Darul Ehsan, Malaysia
Tel +603 5629 3688 Fax +603 5636 8025

Imported by:
L'ORÉAL MALAYSIA SDN BHD
Crown Penthouse, 1 Powerhouse, No. 1, Persiaran Bandar Utama
Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia
Tel 1300 22 2232 Email Customerservice.MY@loreal.com



L'ORÉAL
Dermatological Beauty **PRO**

SCAN HERE TO KNOW MORE

FOR HEALTHCARE
PROFESSIONALS ONLY

MYSG/LRP/ATH/004/0825

ACHIEVE LASTING CHANGE



DUPIXENT is indicated for the treatment of adults and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis who require chronic treatment and whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUXIEN can be used with or without topical corticosteroids.¹

RAPID AND SUSTAINED CONTROL – CONSISTENT ACROSS ALL AGES

- » Sustained improvement of itch, skin clearance, and QoL up to 52 weeks, with rapid control after first dose¹⁻¹⁶

UNIQUE LONG-TERM SAFETY PROFILE

- » With 5 years long-term safety data in adults¹⁷
- » Approved in patients as young as 6 months¹

START WITH EASE, STAY WITH CONFIDENCE

- » DUXIEN is not an immunosuppressant¹
- » 87% Adult patient satisfaction with DUXIEN treatment at 3 years¹⁸

~38,075 PATIENTS TREATED WITH DUXIEN IN RWE STUDIES¹⁹

For the full prescribing information, please scan the QR Code or visit the link provided. Full prescribing information is also available upon request from:



DUPIXENT MY PI
<https://surl.sanofi.com/dupixentmy>

Sanofi-Aventis (Malaysia) Sdn Bhd (334110-P),
Unit TB-18-1, Level 18, Tower B, Plaza 33,
No. 1 Jalan Kemajuan, Seksyen 13, 46200 Petaling Jaya,
Selangor Darul Ehsan, Malaysia.
Tel: 03 7651 0800, Fax: 03 7651 0805.



DUPIXENT SG PI
<https://surl.sanofi.com/dupixentsg>

Sanofi-Aventis Singapore Pte Ltd,
38 Beach Road #18-11,
South Beach Tower, Singapore 189767.
Tel: 65 6226 3836, Fax: 65 6535 5836.



QoL, quality of life; RWE, real-world experience.

References: 1. DUPIXENT Singapore Prescribing Information, July 2023 and Malaysia, October 2023. 2. Blauvelt A et al. *Lancet* 2017; 389:2287–2303. 3. Data on file (AD-1224 CSR). Sanofi and Regeneron Pharmaceuticals, Inc. 2016. 4. Blauvelt A et al. *Lancet* 2017; 389:2287–2303. [suppl.]. 5. Data on file (AD-1224 CSR DLQI rate). Sanofi and Regeneron Pharmaceuticals, Inc. 2021. 6. Data on file (AD-1652 CSR EASI). Sanofi and Regeneron Pharmaceuticals, Inc. 2019. 7. Data on file (AD-1652 CSR CDLQI rate). Sanofi and Regeneron Pharmaceuticals, Inc. 2019. 8. Paller AS et al. *J Am Acad Dermatol* 2020; 83(5):1282–1293. 9. Cork MJ et al. Poster presented at the Revolutionizing Atopic Dermatitis Conference; 2021; June 13; Virtual Conference. Poster 468. 10. Data on file (AD-1652 CSR pruritus NRS). Sanofi and Regeneron Pharmaceuticals, Inc. 2019. 11. Simpson EL et al. *JAMA Dermatol* 2020; 156(1):44–56. 12. Data on file (AD-1526 CSR EASI). Sanofi and Regeneron Pharmaceuticals, Inc. 2019. 13. Paller AS et al. *Am J Clin Dermatol* 2020; 21:119–131. 14. Data on file (AD-1539 EASI). Sanofi and Regeneron Pharmaceuticals, Inc. 2022. 15. Data on file (AD-1539 pruritus NRS). Sanofi and Regeneron Pharmaceuticals, Inc. 2022. 16. Data on file (AD-1539 CDLQI). Sanofi and Regeneron Pharmaceuticals, Inc. 2022. 17. Beck LA et al. Poster presented at the 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference; April 29–May 1, 2023; Washington, DC, USA. 18. Strober B et al. Poster presented at the American Academy of Dermatology Annual Meeting (AAD 2022); March 25–29, 2022; Boston, MA, USA. Poster 33120. 19. Data on file, Regeneron Pharmaceuticals, Inc.

For Healthcare Professionals only

sanofi | REGENERON®

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-SG-2300377-1.0-01/2024

DUPIXENT®
(dupilumab)

SYMPOSIUM 1 - Hot Topics That Matters

**THE IMPORTANCE OF MEDICAL INDEMNITY: PROTECTING DOCTORS
WHEN THINGS GO WRONG**

Sharmini a/p Ganasegaran

Medical Protection Society, Malaysia

This presentation, titled 'The importance of Indemnity: Protecting Doctors When Things Go Wrong' provides an overview of professional indemnity and the different forms of protections available to doctors in Malaysia. It highlights why securing indemnity is essential and explains how it supports doctors in the event of an adverse outcome or clinical error.

SYMPOSIUM 1 - Hot Topics That Matters

**THE IMPORTANCE OF MEDICAL INDEMNITY: PROTECTING DOCTORS
WHEN THINGS GO WRONG**

Kaema Nadarajan a/p Nadarajan, Sharmini a/p Ganasegaran

Medical Protection Society, Malaysia

This presentation, titled 'The importance of Indemnity: Protecting Doctors When Things Go Wrong' provides an overview of professional indemnity and the different forms of protections available to doctors in Malaysia. It highlights why securing indemnity is essential and explains how it supports doctors in the event of an adverse outcome or clinical error.

SYMPOSIUM 1 - Hot Topics That Matters

EXPERT WITNESS AND THE COURTS

Harikannan Ragavan

Jayadeep, Hari and Jamil (JHJ), Kuala Lumpur, Malaysia

This talk explores the evolving role of expert witnesses in medical negligence litigation, focusing on their responsibilities, challenges, and impact on court proceedings. It will examine the legal expectations of expert testimony. Drawing on practical examples and some cases, the session aims to equip clinicians with insights into navigating medico-legal complexities while upholding professional integrity and public trust.

SYMPOSIUM 2 - Paediatric Dermatology**PAEDIATRIC CONTACT DERMATITIS: WHAT IS IMPORTANT?****Nur Aileen Wee Abdullah**

Growell Baby and Child Specialist Clinic (Ampang), Selangor, Malaysia

Contact dermatitis is more common in children due to their thinner and more sensitive skin. However, they are usually misdiagnosed due to the nature of the rash resembling itchy eczema flare, and the fact that most of them do have underlying atopic dermatitis.

Strong suspicion and sound clinical knowledge are required to clinch the diagnosis. Many needs topical anti-inflammatory to treat the rash. However, identifying and eliminating the culprit is the mainstay of management.

I hope this presentation can shed some insights as to the essential points for this topic, especially in identifying the various culprit of contact dermatitis.

SYMPOSIUM 2 - Paediatric Dermatology**ANOGENITAL SKIN DISEASES IN CHILDREN AND ADOLESCENTS****Henrietta Albela**

Sarawak General Hospital, Sarawak, Malaysia

Anogenital skin conditions encompass a broad spectrum of dermatological disorders affecting the perianal and genital regions. The differential diagnoses vary according to the patient's age and may range from common irritant reactions, such as diaper dermatitis, to more complex inflammatory, infectious, or congenital conditions. Importantly, the potential for sexual abuse must always be considered in pediatric cases, necessitating careful and thorough clinical evaluation. A structured and systematic diagnostic approach is essential to ensure accurate diagnosis, minimize unnecessary investigations, and reduce distress for both the child and their caregivers.

SYMPOSIUM 2 - Paediatric Dermatology**USE OF JAK INHIBITOR IN PAEDIATRIC DERMATOLOGY****Leong Kin Fon**

Tunku Azizah Hospital, Kuala Lumpur, Malaysia

The advent of Janus kinase (JAK) inhibitors has transformed the treatment landscape of immune-mediated skin disorders. By selectively targeting the JAK-STAT signalling pathway, these small molecules interrupt key cytokine circuits implicated in atopic dermatitis, alopecia areata, vitiligo, and other chronic inflammatory conditions. In paediatric dermatology, where therapeutic options are often limited and long-term safety is paramount, JAK inhibitors offer a novel and promising approach. This lecture will review the scientific rationale for JAK inhibition, summarise current clinical trial data and real-world experience in children, and discuss practical considerations in prescribing - including dosing, monitoring, and safety concerns. Case illustrations will highlight potential benefits and challenges in day-to-day practice. Finally, we will explore unanswered questions and future directions for integrating JAK inhibitors into paediatric dermatology care.

MORNING FOCUS 1

BEYOND THE SURFACE: OPTIMIZING HAND ECZEMA MANAGEMENT THROUGH SKIN pH CONTROL AND BARRIER SUPPORT

Ch'ng Chin Chwen

Subang Jaya Medical Centre, Selangor, Malaysia

Hand eczema (HE) is a complex inflammatory skin disorder on hands and/or wrists. Chronic hand eczema (CHE) is appropriate in cases that persist for more than three months or recur two or more times within a 12-month time frame. Typical clinical signs include redness, thickening of the skin, scaling, edema, vesicles, areas of hyperkeratosis, cracks (fissures), and erosions. HE is not merely eczema on the hands, but it can significantly impact a person's day-to-day life. This condition can be incredibly debilitating, significantly impacting patients' lives.

Many studies show that elevated skin pH and compromised skin barrier function are key factors in HE pathogenesis. Study found significantly higher skin pH levels and increased transepidermal water loss, which signifies an impaired skin barrier function, in both lesional and non-lesional skin of chronic hand eczema patients compared to normal skin of healthy individual. In fact, because of these inherent predisposing factors of hand eczema, the skin becomes more vulnerable to external irritants and prone to dryness and flare-ups. As a result, chronic inflammation can persist even after complete avoidance of initial triggers.

Ceradan® Advanced Hand Balm addresses these issues with its unique ability to sustainably lower skin pH with patented active pH control technology and significantly improving skin ceramide content to restore skin barrier with an optimal 3:1:1 ceramide-dominant ratio of essential skin lipids. Enriched with naturally-derived licorice extract for anti-inflammatory and antipruritic benefits, it may help to soothe and calm irritated and inflamed hands.

PRE-LUNCH SYMPOSIUM 1

EXPANDING HORIZONS: EMERGING ROLES OF APREMILAST IN PSORIASIS MANAGEMENT

Low Dy-Win

Sunway Medical Center Penang, Penang, Malaysia

Psoriasis is associated with multiple comorbidities and results in huge physical, emotional and social affliction. Collectively, the low satisfaction with psoriasis treatment, the rates of untreated and undertreated patients, frequent treatment switching, and the extensive use of combination therapy in the efforts of trying to attain a satisfactory response denote unmet treatment needs in patients with psoriasis of all severities.

Apremilast is a phosphodiesterase 4 (PDE4) inhibitor, administered orally, which is approved for the treatment of plaque psoriasis and psoriatic arthritis. Compared to the other currently available medications used to treat plaque psoriasis, apremilast has a favourable safety profile.

PRE-LUNCH SYMPOSIUM 2

PIONEERING LASTING SKIN CLEARANCE AND MEMORY RESET IN PSORIASIS WITH GUSELKUMAB**Annika Smith**

St Vincent's Private Hospital, Australia

Psoriasis is a chronic immune-mediated condition in which pathogenic T cell subsets, including tissue-resident memory T cells (TRMs), drive disease persistence and recurrence even after apparent clinical remission. Interleukin-23 (IL-23) plays a pivotal role in TRM maintenance and pathogenic cytokine production, making IL-23 inhibitors a rational therapeutic approach for durable disease control.

This session will explore the evolving understanding of TRMs in psoriasis pathophysiology, with emphasis on their role in relapse and the concept of "memory reset" through targeted IL-23 blockade. Key real-world evidence (RWE) and pivotal clinical trial data, including the GUIDE study, will be presented to illustrate the impact of guselkumab on sustained clearance, treatment persistence, and potential disease modification. Practical insights from local case experience will highlight best practices for optimising outcomes, individualising treatment, and differentiating guselkumab from other IL-23 inhibitors in the Asia-Pacific context.

LUNCH SYMPOSIUM 1

TRIFAROTENE: A BREAKTHROUGH IN ACNE CARE - REAL-WORLD INSIGHTS**Azura Mohd Affandi**

Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Acne vulgaris poses a multifaceted burden - extending beyond skin to deeply affect emotional wellbeing, social confidence, and quality of life. This presentation explores the pathogenesis, burden, and treatment of acne sequelae - specifically atrophic scars and post-inflammatory hyperpigmentation (PIH) - with a focus on the evolving role of topical retinoids. These findings highlight the potential of trifarotene not only as a first-line treatment for facial and truncal acne but also as a valuable agent in preventing and managing acne sequelae, including in skin of color.

LUNCH SYMPOSIUM 1**ROLE OF DERMOCOSMETIC IN SENSITIVE SKIN FOCUSING ON THE ROLE OF MOISTURISERS****Kwan Zhenli**

Hospital Subang Jaya Medical Centre, Selangor, Malaysia

Sensitive skin is more than a subjective complaint - it is now recognized as a dermatological condition with measurable structural and functional changes. Recent imaging and molecular studies reveal key alterations in epidermal morphology, including disrupted stratum corneum, vascular changes, and heightened neuroinflammatory responses. These insights underscore the need for targeted therapeutic strategies beyond conventional emollients. This session explores how advanced dermocosmetics can holistically address sensitive skin by restoring barrier function and mitigating neuroinflammation. Through a "Target-Lock-Connect" approach, key actives such as niacinamide, panthenol, and glycerin demonstrate efficacy in reinforcing the barrier, reducing sensory discomfort, and improving patient satisfaction. Clinical evidence, in vitro data, and consensus-based guidance from Asian dermatology experts are presented to support practical, evidence-led skincare routines. By bridging science and patient needs, dermocosmetics emerge as essential adjuncts in modern dermatologic care for sensitive skin.

LUNCH SYMPOSIUM 2**SHINGLES: BEYOND THE RASH - EMPOWERING PHYSICIANS IN PREVENTION****Tan Kit Mun**

Subang Jaya Medical Centre, Selangor, Malaysia

Shingles poses a significant burden for older adults, especially those with comorbidities like diabetes and cardiovascular disease, which increase the risk by 30% and 34%, respectively. This session will provide physicians with key insights into the importance of prioritising shingles vaccination in vulnerable populations. Dr. Tan will discuss the clinical rationale for vaccination, the safety and efficacy of the Shingrix vaccine, and its role in reducing healthcare resource use. The session aims to equip healthcare providers with strategies to integrate vaccination into routine care, improving patient outcomes and supporting healthy aging through targeted, evidence-based prevention strategies.

SYMPOSIUM 3 - Important Laboratory Supports in Dermatology**LABORATORY DIAGNOSTIC WORK UP FOR GENODERMATOSES: WHAT IS IMPORTANT?****Leong Kin Fon**

Tunku Azizah Hospital, Kuala Lumpur, Malaysia

Genodermatoses comprise a diverse group of inherited skin disorders with significant diagnostic and management challenges. Advances in molecular genetics have expanded the range of laboratory tools available, but the key lies in knowing which tests to select and how to interpret them in a clinically meaningful way. This lecture will provide a practical overview of the laboratory diagnostic work up for genodermatoses, from basic histopathology and immunofluorescence studies to next-generation sequencing, copy number analysis, and functional assays. Emphasis will be placed on how to integrate clinical clues with laboratory results, the importance of multidisciplinary collaboration, and the pitfalls of over- or under-investigation. Case vignettes will highlight the diagnostic journey from bedside to bench, illustrating when a simple test suffices and when advanced molecular analysis is warranted. Participants will leave with a clearer framework for approaching genodermatoses in practice, ensuring accurate diagnosis, better patient counselling, and improved care pathways.

SYMPOSIUM 3 - Important Laboratory Supports in Dermatology**IMPORTANT PCR TESTS IN DERMATOLOGY****Tang Min Moon**

Hospital Umum Sarawak, Sarawak, Malaysia

The practice of dermatology in the era of AI should leverage more molecular diagnostics i.e. PCR tests, with high sensitivity and specificity to improve the accuracy and speed of diagnosis in infectious dermatoses, especially in the identification of difficult-to-culture pathogens. Quantitative PCR, which can measure the amount of pathogen nucleic acid, may provide insights of severity and monitor the response to treatment. Furthermore, antimicrobial resistance can be detected using PCR to guide the antimicrobial therapy. Many PCR tests in Dermatology can be performed on skin samples which are obtained in non-invasive or minimally invasive ways such as skin swabs, scrapings or biopsy.

SYMPOSIUM 3 - Important Laboratory Supports in Dermatology**LAB TESTS FOR "ALLERGY": HOW TO INTERPRET?****Chai Zi Teng**

Singapore General Hospital, Singapore

Laboratory tests are essential for diagnosing allergic diseases, aiding in identification of specific allergens. Common tests include serum specific IgE and component-resolved diagnostics. However, test results must be interpreted alongside clinical history, as sensitization does not always indicate clinical allergy. Proper test selection and interpretation are crucial for accurate diagnosis and effective management.

SYMPOSIUM 4 - Sensitive Skin and Scars

FROM LASERS TO INJECTABLES: STRATEGIC INTEGRATION IN ACNE SCAR MANAGEMENT

Thanya Techapichetvanich

Siriraj Hospital, Mahidol University, Bangkok, Thailand

Effective management of acne scars often requires a multimodal approach that addresses the diverse morphological characteristics of scarring, ranging from atrophic to hypertrophic patterns. This lecture explores the strategic integration of lasers and injectables to achieve optimal, individualized outcomes in acne scar treatment. We will examine the synergistic use of ablative and non-ablative lasers for resurfacing and collagen remodeling, alongside injectables such as dermal fillers, subcision-enhancing agents, and biostimulators to improve volume loss and tissue tethering. Emphasis will be placed on patient selection, sequencing of treatments, anatomical considerations, and how to tailor interventions based on scar type, skin type, and downtime tolerance. Clinical protocols, safety tips, and real-world case examples will be shared to illustrate how combining technologies can elevate efficacy, reduce recurrence, and enhance patient satisfaction. By the end of the session, attendees will gain a comprehensive framework for holistic and personalized acne scar management using both energy-based devices and injectable therapies.

SYMPOSIUM 4 - Sensitive Skin and Scars

SURGICAL MANAGEMENT OF KELOIDS AND HYPERTROPHIC SCAR

Richard John Barlow

St John's Institute of Dermatology, United Kingdom

Hypertrophic scars (including keloids) arise from abnormal wound healing and are different in terms of aetiology, clinical morphology and histopathology.

This lecture addresses the importance of excisional techniques with adjunct therapies such as massage, silicone and pressure dressings, as well as with intralesional corticosteroids.

Other non-surgical interventions should be considered in relation to scar:

- a) Colour and
- b) Contour, ie depending on whether it is:
 - Hypertrophic, the subject of this lecture, or
 - Atrophic (and, if so, whether distensible or non-distensible)

Keloids are a subset of hypertrophic scars and especially likely to recur if excised, unless if allowed to granulate and with interventions such as intralesional steroids and/or radiotherapy. A CO2 laser allows dissection of the keloid in a plane just below the hair follicles. They are particularly problematic off the head and neck.

Surgical revision of hypertrophic scars may preclude some non-surgical options and create new problems.

- a) *Pre-operative interventions* include setting expectations, reviews of diet and smoking as well as optimising co-morbidities.
- b) *Surgery* should not just repeat what has been attempted previously and in similar circumstances. Consideration should be given to the tissue reserve and free margins. Reconstruction should be performed with reference to the borders of cosmetic areas and to the relaxed skin tension lines. Wound tension should be minimised by appropriate reconstructive planning, use of dermal sutures and fine, percutaneous stitches. Z-plasties can correct wound-healing which is misaligned or contracted and, like W-plasties, can break up and otherwise enhance the appearance of long, linear scars.
- c) *Post-operative management* should optimise wound care and prevention of complications. Botulinum toxin and fractional laser techniques may improve some scar healing.

SYMPOSIUM 4 - Sensitive Skin and Scars**SENSITIVE SKIN SYNDROME: CURRENT UNDERSTANDING****Ch'ng Chin Chwen**

Subang Jaya Medical Centre, Selangor, Malaysia

Sensitive Skin Syndrome (SSS) is a common yet underrecognized dermatological condition characterized by unpleasant sensory symptoms - such as stinging, burning, itching, or tightness - in response to stimuli that typically should not provoke such sensations. These symptoms often occur in the absence of visible skin changes, making diagnosis and management particularly challenging.

SSS has a complex pathophysiology, including barrier dysfunction, neurogenic inflammation, and the role of transient receptor potential (TRP) channels, particularly TRPV1.

There's emerging data on potential therapeutic approaches, the role of cosmeceuticals, and the importance of patient education. By consolidating current knowledge, clinicians can recognise and treat patients with sensitive skin more effectively with practical management strategies.

EVENING FOCUS 1**SECURING WINDOW OF OPPORTUNITY IN PSORIASIS****Colin Theng Thiam Seng**

The Skin Specialists and Laser Clinic, Singapore

Psoriasis is a chronic disease with a wide spectrum of clinical manifestations and associated with various comorbidities. Delays in diagnosis and treatment can lead to irreversible joint damage and increased mortality due to cardiovascular disease.

Early biologic treatment can stop the ongoing disease progression. Clinical trials have shown that Secukinumab is an effective biologic therapy in achieving fast and long-lasting skin clearance, including difficult-to-treat areas, with proven efficacy in other manifestations including joint.

Given the significant disease burden of psoriasis and its substantial impact on patient's life, early intervention within "window of opportunity" with optimal treatment is crucial for improved psoriasis patient outcomes.

EVENING FOCUS 2

BREAKTHROUGHS IN HYPERPIGMENTATION & PHOTOPROTECTION

Kok Wai Leong

HMI Medical Centre, Singapore

Hyperpigmentation disorders, including solar lentigo and post-inflammatory hyperpigmentation, are highly prevalent and significantly impact patients' quality of life. While multiple treatments exist, long-term outcomes remain limited due to side effects and persistent recurrence. Emerging research highlights the critical role of UVA1 and oxidative stress in pigmentation and barrier dysfunction, reinforcing the need for comprehensive photoprotection. Anthelios UVMUNE 400 Anti-Dark Spot Fluid, powered by Mexoryl 400 and MelasyI™, offers superior defense against ultra-long UVA rays while targeting melanin precursors. Clinical studies demonstrate its efficacy in reducing dark spot size, intensity, and visibility, advancing evidence-based care in pigmentation management.

SYMPOSIUM 5 - Nasty Infections in Dermatology

RECALCITRANT NON-GENITAL CUTANEOUS WARTS: A REVIEW OF THE TREATMENT OPTIONS

Pan Jiun Yit

National Skin Centre, Singapore

Viral warts on non-genital areas may be recalcitrant and extremely challenging to treat, affecting the patients' quality of life. Besides cryotherapy, electrocautery and CO2 laser, the options of immunotherapy using intralesional MMR / vitamin D, Gardasil and Diphenycprone will be discussed, along with other emerging options.

SYMPOSIUM 5 - Nasty Infections in Dermatology

TREATMENT-RESISTANT LEPROSY: HOW TO MANAGE?

Rajalingam Ramalingam

Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia

Despite leprosy being curable with effective multidrug therapy, the disease is still transmitted worldwide with a plateau of 200,000 new cases annually, including around 10% of children. One of the reasons this is so is due to antimicrobial resistance to antileprosy drugs. With a prolonged incubation period coupled with an inability to culture the bacilli in vitro, challenges towards antimicrobial resistance surveillance arise. This lecture aims to highlight antimicrobial resistance in leprosy, and strategies to manage it.

SYMPOSIUM 5 - Nasty Infections in Dermatology

THE ALARMING RECALCITRANT DERMATOPHYTOSIS**Pan Jiun Yit**

National Skin Centre, Singapore

Tinea infections are extremely common in the tropics. Many patients suffer from relapsing and recalcitrant dermatophyte infections which are extremely uncomfortable and which may spread to close contacts or family members. We explore the continuum and challenges of emerging dermatophyte species including *Trichophyton indotineae*, as well as the looming threat of antifungal resistance.

SYMPOSIUM 6 - Risk Management in Dermato-Surgical Procedures

PREVENTING AND MANAGING COMPLICATIONS IN DERMATOLOGIC SURGERY**Richard John Barlow**

St John's Institute of Dermatology, United, Kingdom

All surgical procedures have potential complications though pigmented skin may present special challenges. Thorough pre-operative assessment is important and includes patient selection, surgical planning and good surgical technique including layered closure.. Key risk factors include anti-coagulant use, smoking, diabetes and immunosuppression. Patients should be fully informed as to what complications may occur and with what likelihood and consequences.

Complications of (or associated with) common procedures can be classed as:

- a) Peri-operative
 - bleeding
 - nerve damage
 - allergy/ contact reactions
 - infection
 - other causes of poor wound healing
- b) Delayed
 - hypergranulation and erythema/telangiectasia
 - dyspigmentation
 - scarring

When a complication does occur, it benefits all parties if it is recognised quickly, discussed candidly with the patient and managed openly and rationally.

SYMPOSIUM 6 - Risk Management in Dermato-Surgical Procedures**RISKS OF FILLERS IN DERMATOLOGY: HOW TO MANAGE THEM?****Thanya Techapichetvanich**

Siriraj Hospital, Mahidol University, Bangkok, Thailand

With the widespread use of dermal fillers in aesthetic dermatology, the potential for serious adverse events, particularly vascular occlusion, demands heightened awareness and preparedness among practitioners. This lecture will focus on emergency complications, specifically vascular occlusion, covering both non-visual involvement (e.g., skin ischemia) and visual involvement (e.g., retinal artery occlusion). Emphasis will be placed on early and accurate identification of signs and symptoms, as well as the use of screening tests to support timely diagnosis. A thorough understanding of essential facial vascular anatomy will be reviewed to aid in both prevention and targeted intervention. The session will outline step-by-step management protocols, including the effective use of hyaluronidase, warm compresses, adjunctive therapies, and referral criteria for ophthalmologic emergencies. We will also briefly address delayed filler complications to round out the clinician's approach to comprehensive filler safety. Attendees will leave equipped with practical strategies to recognize, assess, and manage filler-related emergencies with confidence and precision.

SYMPOSIUM 6 - Risk Management in Dermato-Surgical Procedures**MINIMIZING COMPLICATIONS OF LASER TREATMENT IN SKIN OF COLOURS****Henry Foong Boon Bee**

Foong Skin Specialist Clinic, Ipoh, Perak, Malaysia

The increasing demand for aesthetic and therapeutic procedures utilizing lasers and energy-based devices (EBDs) in patients with skin of color necessitates a thorough understanding of the unique challenges posed by this diverse population. Melanin-rich skin is inherently more susceptible to complications such as post-inflammatory hyperpigmentation (PIH), hypopigmentation, scarring, and paradoxical hyperpigmentation, often resulting from improper parameter selection or inadequate pre- and post-treatment care. This lecture will explore the underlying mechanisms behind these adverse outcomes, emphasizing the importance of tailoring treatments to minimize risks while achieving optimal results.

The lecture will delve into evidence-based strategies for selecting appropriate devices, wavelengths, and energy parameters suitable for skin of color. By discussing practical approaches to patient assessment, including Fitzpatrick skin typing and individualized risk analysis, delegates will gain actionable insights into pre-treatment planning and intra-procedure modifications. Additionally, case studies will illustrate the effective use of picosecond lasers, fractional resurfacing technologies, and long-pulse Nd:YAG lasers, highlighting both successes and lessons learned in managing complications in darker skin types.

Finally, the lecture will address post-procedure care and advanced therapeutic interventions for managing complications when they arise, from topical regimens to innovative laser correction techniques. By combining clinical expertise, evidence-based recommendations, and an understanding of the unique needs of patients with skin of color, this presentation aims to empower delegates with the tools to provide safer and more effective dermatologic care, ultimately promoting patient trust and satisfaction.

SYMPOSIUM 7 - Targeted Therapies and The Associated Dermatological Adverse Events - What Do We Do?**CUTANEOUS TOXICITY OF EGFR INHIBITORS****Tang Min Moon**

Hospital Umum Sarawak, Sarawak, Malaysia

When compared to conventional chemotherapy, the mechanism of action of targeted therapies in cancers is aimed to cause fewer collateral adverse events. Epidermal growth factor receptor (EGFR) inhibitors, however, are known to cause multiple nasty cutaneous toxicities which lead to significant morbidity, severe impairment of quality of life and interruption/cessation of the treatment. This is because EGFR itself plays a vital role in numerous physiological processes and biological homeostasis of the skin, including differentiation, wound healing, and epidermal growth. Preemptive preventive measures, early recognition of cutaneous toxicities, and aggressive management are vital to ensure their overall success in cancer treatment.

SYMPOSIUM 7 - Targeted Therapies and The Associated Dermatological Adverse Events - What Do We Do?**DERMATOLOGICAL ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS****Chai Zi Teng**

Singapore General Hospital, Singapore

Laboratory tests are essential for diagnosing allergic diseases, aiding in identification of specific allergens. Common tests include serum specific IgE and component-resolved diagnostics. However, test results must be interpreted alongside clinical history, as sensitization does not always indicate clinical allergy. Proper test selection and interpretation are crucial for accurate diagnosis and effective management.

SYMPOSIUM 7 - Targeted Therapies and The Associated Dermatological Adverse Events - What Do We Do?**ADVERSE EVENTS OF SPECIAL INTERESTS FROM COMMON BIOLOGICS & SMALL MOLECULES USED IN DERMATOLOGY****Felix Yap Boon Bin**

Sunway Medical Centre, Selangor, Malaysia

Biologics have been used in Malaysia for the past 12 years initially in the treatment of psoriasis and later expanding into the treatment of urticaria, eczema, hidradenitis suppurativa and prurigo nodularis. For the past 4 years, small molecules have been successfully used in the treatment of eczema and later alopecia areata. With the increasing usage of such medications, adverse effects are aplenty. It is important for practising clinician to know the common side effects of these medications. This will allow for better shared decision making with our patients in the management of their skin diseases.

SYMPOSIUM 8 - All about Aging

PHOTOPROTECTION AND SYSTEMIC ANTIOXIDANTS**Teeba Raja**

Hospital Selayang, Selangor, Malaysia

Photoprotection is central to preventing photoaging, carcinogenesis, and pigmentary disorders. While sunscreens effectively reduce actinic keratoses, squamous cell carcinoma, and melanoma, limitations include poor compliance and inadequate protection against visible light and infrared radiation. Systemic agents offer adjunctive benefits. Polypodium leucotomos extract reduces UV erythema and benefits polymorphous light eruption, melasma, and photoaging. Nicotinamide shows the strongest evidence, lowering non-melanoma skin cancer risk in high-risk patients. Carotenoids, vitamin C, and vitamin E provide additional antioxidant and anti-MMP effects. Though not sunscreen substitutes, systemic antioxidants complement topical measures in skin cancer prevention, pigmentation control, and photoaging management.

SYMPOSIUM 8 - All about Aging

WHAT IS NEW IN MANAGING ANDROGENETIC ALOPECIA**Sean Yong Shin Shen**

Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia

Androgenic alopecia (AGA) remains one of the most common hair loss disorders, with significant psychosocial impact. Recent advances in pathogenesis understanding, diagnostic tools, and therapeutic options have transformed its management. Low dose oral minoxidil, new topical formulations, and other procedural advances are redefining the therapeutic landscape for androgenic alopecia, offering patients safer, more effective, and personalized solutions. Future directions for AGA treatment include Genetic and microbiome-based personalized therapies.

MORNING FOCUS 3

TALK OF THE TOWN: THE TIME FOR GIP IS NOW**Jeyakantha Ratnasingam**

Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia

1. Mechanism of action of Tirzepatide - the novel GIP/GLP-1 receptor agonist.
2. Key safety and efficacy data from pivotal phase 3 trials:
 - a. SURMOUNT-1
 - b. SURMOUNT-1 Three-Year-Study
 - c. SURMOUNT-5

PLENARY LECTURE 2 - Malcolm Greaves Memorial Lecture**MELANOMA IN SKIN OF COLOUR****Linda Martin**

University of New South Wales and Melanoma Institute Australia, Australia

Early accurate recognition of melanoma in skin of colour is essential to improve outcomes. Melanoma in patients with skin of colour is associated with delayed diagnosis, diagnosis at an advanced stage, and higher mortality rates. The comparative incidence, clinical presentation, molecular pathogenesis and treatment will be contrasted for acral, mucosal and primary cutaneous melanoma in patients with skin of colour. Diagnostic challenges and approaches to improve early detection will be discussed.

SYMPOSIUM 9 - Pigmentary Disorders**NOVEL TREATMENT IN VITILIGO****Tang Jyh Jong**

Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia

Vitiligo is a chronic autoimmune pigmentary disorder with significant psychosocial impact. Traditional therapies, including corticosteroids, calcineurin inhibitors, and phototherapy, often yield variable results and limited long-term repigmentation. Recent advances in understanding vitiligo immunopathogenesis have led to novel targeted therapies. Janus kinase (JAK) inhibitors, both topical and systemic, show promising efficacy in halting disease progression and inducing repigmentation. Emerging biologics directed against key cytokines such as IL-15 are under investigation. These innovative approaches represent a paradigm shift, offering potential for more durable, individualized, and effective management strategies in vitiligo care.

SYMPOSIUM 9 - Pigmentary Disorders**COSMECEUTICALS FOR MELASMA****Felix Yap Boon Bin**

Sunway Medical Centre, Selangor, Malaysia

Melasma is a common condition affecting mainly women. Various topical medications are used successfully to manage this condition. However, there are many skin care products and cosmeceuticals that are introduced in the market to manage this condition. Most of these cosmeceuticals are available over the counter. Clinicians and dermatologists need to be aware of such products to be able to advise their patients appropriately. Knowledge about the efficacy and safety of these products especially the common ones will have to guide patients for a optimal management of their skin condition.

SYMPOSIUM 9 - Pigmentary Disorders**PIGMENTED NAILS IN SKIN OF COLOR: HOW TO APPROACH?****Sean Yong Shin Shen**

Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia

Pigmented nail disorders in skin of colour present unique diagnostic and therapeutic challenges, often requiring careful differentiation between benign melanonychia, subungual hemorrhage, and malignant melanoma. This presentation reviews key clinical pearls for evaluation, including dermoscopic patterns, patient history, and risk stratification. Emphasis is placed on high-risk features warranting biopsy and investigations, with updates in management - from longitudinal melanonychia monitoring to surgical interventions for suspicious lesions. By integrating evidence-based guidelines with culturally sensitive care, clinicians can optimize early detection and outcomes for these complex cases.

SYMPOSIUM 10 - Toxins**OPTIMISING FACIAL BOTULINUM TOXIN RESULTS****Melinda Tong Mui Leng**

Specialist Skin Clinic, Sabah, Malaysia

This review will cover approaches to optimize both aesthetic and functional results of facial botulinum toxin.

SYMPOSIUM 10 - Toxins**NON-COSMETIC DERMATOLOGICAL USE OF BOTULINUM TOXIN****Teeba Raja**

Hospital Selayang, Selangor, Malaysia

Botulinum toxin, widely recognized for cosmetic applications, has significant therapeutic potential in dermatology beyond aesthetics. Its mechanism of blocking acetylcholine release and modulating neuropeptides, extends to conditions involving hyperhidrosis, pain, and inflammation. FDA approval exists for severe axillary hyperhidrosis, with robust trial evidence supporting efficacy. Off-label uses include hyperhidrosis, acantholytic disorder, pruritic disorders, inflammatory disorders, painful disorders, scarring and ulceration. Clinical studies and case series demonstrate meaningful symptomatic improvement with generally favourable safety. Botulinum toxin represents a valuable adjunct in dermatological practice, broadening treatment strategies for refractory and quality-of-life-limiting conditions.

PRE-LUNCH SYMPOSIUM 3**TILDRAKIZUMAB: ILLUMINATING NEW HORIZONS IN PSORIASIS CARE****Felix Yap Boon Bin**

Sunway Medical Centre, Selangor, Malaysia

Psoriasis is a chronic, immune-mediated disease with a significant impact on patients' quality of life and associated comorbidities such as metabolic syndrome. The emergence of targeted biologic therapies has transformed disease management, particularly with the introduction of IL-23 inhibitors. This session will provide an overview of Ilumya (tildrakizumab), focusing on its selective IL-23 mode of action and its role in modulating pathogenic T-cell responses in psoriasis. Efficacy and safety evidence will be highlighted through a review of landmark RESURFACE 1 and RESURFACE 2 trials, which established tildrakizumab as a durable and well-tolerated treatment option. In addition, the latest updates from the American Academy of Dermatology (AAD) poster presentations on metabolic syndrome and its association with psoriasis will be discussed, further emphasizing the importance of holistic patient management. Finally, real-world perspectives will be shared through case studies of both biologic-naïve and biologic-experienced patients, illustrating practical treatment considerations, response patterns, and long-term disease control.

PRE-LUNCH SYMPOSIUM 4**BEYOND THE HIVES: ELEVATING PATIENT CARE IN CHRONIC URTICARIA****Azura Mohd Affandi**

Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Chronic urticaria remains a complex condition that demands more than short-term symptom relief. In this session, Dr. Azura Mohd Affandi will explore a patient-centric approach to managing urticaria, emphasising early optimisation of non-sedating, long-acting antihistamines with proven safety and efficacy - even at higher doses - as the foundation of treatment. She will also highlight the role of advanced therapies with targeted mechanisms for antihistamine-refractory cases, referencing both local guidelines and international best practices. Real-world patient scenarios and practical escalation strategies will be shared to guide clinicians on when and how to step up therapy, with the ultimate goal of achieving sustained disease control and improving patient quality of life.

LUNCH SYMPOSIUM 3**RESTORING THE EPIDERMAL BARRIER: WHY SKIN IDENTICAL CERAMIDES MATTER****Mok Zhun Rui**

The Dermatology Practice and Gleneagles Hospital, Singapore

Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by genetic, immunological, and environmental factors, with impaired epidermal barrier function at its core. Barrier dysfunction leads to increased transepidermal water loss, altered ceramide composition, and heightened susceptibility to allergens and inflammation. These mechanisms contribute to pruritus, sleep disturbances, psychological distress, and reduced quality of life. Restoring barrier integrity is therefore central to management. Evidence supports the use of ceramide-containing moisturizers, which replenish deficient lipids, enhance hydration, and reduce AD severity. Clinical studies demonstrate improved outcomes in both pediatric and adult patients, reinforcing ceramides as a cornerstone of AD care.

LUNCH SYMPOSIUM 3

RESTORING THE EPIDERMAL BARRIER: WHY SKIN IDENTICAL CERAMIDES MATTER**Evelyn Yap Wen Yee**

Mahkota Medical Centre, Melaka, Malaysia

Eczema, or atopic dermatitis, is a chronic inflammatory skin disease characterized by impaired barrier function, increased transepidermal water loss, and lipid deficiencies, especially in ceramides. These alterations drive dryness, itching, and recurrent flares, significantly affecting quality of life. Effective management therefore requires not only controlling inflammation but also restoring the skin barrier. CeraVe is formulated with three essential skin-identical ceramides (1, 3, and 6-II) that replenish deficient lipids and strengthen barrier integrity. Combined with Multivesicular Emulsion (MVE) technology, CeraVe ensures sustained ingredient release, providing long-lasting hydration and repair. Clinical studies demonstrate efficacy across age groups, reinforcing its role in eczema care.

LUNCH SYMPOSIUM 4

ADVANCING THE PARADIGM: JAK INHIBITION IN ATOPIC DERMATITIS AND ALOPECIA AREATA**Adelaide Hebert**

The University of Texas Medical School, United States

This topic explores the role of Janus kinase inhibitors (JAKi) in treating atopic dermatitis (AD) and alopecia areata (AA), focusing on abrocitinib and ritlecitinib. By targeting the JAK-STAT signaling pathway, these inhibitors modulate immune responses, reduce inflammation, and promote hair regrowth. Recent clinical trials highlight their efficacy in improving disease severity and patient quality of life, positioning them as promising alternatives to conventional therapies. Additionally, we will review core pivotal trial data and the latest evidence supporting the use of these JAKi, providing a comprehensive overview of their clinical benefits and potential in dermatology.

CONTROVERSIES

PATCH TESTING PRIOR TO METAL IMPLANTS: IS IT NECESSARY?**Michelle Voo Sook Yee**

Hospital Queen Elizabeth, Sabah, Malaysia

Metal implant related hypersensitivity reactions are rare. The clinical manifestations have been suggested to encompass both local reactions such as local dermatitis, swelling, aseptic loosening and generalized reactions such as systemic contact dermatitis. As there is increasing awareness of the potential allergic reactions to implanted medical devices, dermatologists infrequently receive referrals for preimplantation and post implantation testing. This session will discuss the issues, controversies and expert consensus on metal implant hypersensitivity.

CONTROVERSIES**AUGMENTED REALITY TECHNOLOGY IN AESTHETIC DERMATOLOGY****Rungsima Wanitphakdeedecha**

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Augmented reality (AR) overlays digital information onto real-world views, enhancing visualization, precision, and patient communication in aesthetic dermatology. AR can project anatomical landmarks, injection planes, or treatment simulations directly onto the patient's skin in real time, supporting safer procedures and improved accuracy. It also facilitates education by enabling interactive anatomy demonstrations and treatment previews. By bridging the gap between planning and execution, AR technology has the potential to elevate procedural safety, personalization, and patient satisfaction in aesthetic practice.

CONTROVERSIES**TOPICAL STEROID WITHDRAWAL SYNDROME: SHOULD WE WORRY?****Chang Choong Chor**

Gleneagles Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Topical Steroid Withdrawal Syndrome is a debilitating dermatosis occurring after discontinuation of prolonged use of potent topical corticosteroids (TCS), characterized by intense burning and itch, confluent erythema, flushing and oedema spreading beyond application site. Risk factors include long-term TCS use, inappropriate TCS application without medical supervision, especially on sensitive skin like the face, genital and intertriginous areas. Pathophysiology involves suppression of intrinsic cortisol production within keratinocytes, skin atrophy and barrier dysfunction, rebound vasodilation and inflammation. Differential diagnoses include eczema flare, allergic contact dermatitis, rosacea and skin infections. Treatment strategies focus on gradual withdrawal of TCS, switching to non-steroidal topical anti-inflammatory agent such as calcineurin inhibitors or crisaborole, supportive skin care, symptom management, as well as patient education to prevent recurrence.

PLENARY LECTURE 3**FILLERS IN DERMATOLOGY: THE PAST, THE PRESENT AND THE FUTURE****Rungsima Wanitphakdeedecha**

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Filler rheology - the study of a material's flow and deformation - directly influences the behavior, integration, and clinical performance of dermal fillers. Key parameters such as elasticity (G'), viscosity, and cohesivity determine product suitability for different facial regions, depths, and aesthetic goals. Understanding rheology enables clinicians to select fillers that match tissue characteristics, optimize longevity, minimize complications, and achieve natural outcomes. This knowledge is essential for safe, individualized treatment planning in aesthetic dermatology.

SYMPOSIUM 11 - Dermato-Oncology

THE UNUSUAL PRESENTATIONS OF MALIGNANT MELANOMA**Linda Martin**

University of New South Wales and Melanoma Institute Australia, Australia

Clinical diagnosis of melanoma is often difficult. Despite the high incidence of melanoma in Australia, general population screening is not recommended, partly due to the variable diagnostic accuracy of standard care and lack of evidence that screening reduces mortality. Amelanotic, desmoplastic, naevoid, featureless, ungual and scalp melanoma present diagnostic challenges. Clinical presentation of melanoma in priority populations including children and pregnant women is not well described. Furthermore clinically and histologically borderline melanomas require careful clinicopathological correlation to minimise overdiagnosis and select appropriate treatment. Illustrative cases and non-invasive diagnostic strategies for identification of featureless and unusual melanomas will be presented.

SYMPOSIUM 11 - Dermato-Oncology

APPROACH TO BCC**Kwan Zhenli**

Subang Jaya Medical Centre, Selangor, Malaysia

Basal cell carcinoma (BCC) is the most common keratinocyte cancer which usually affects sun-exposed areas. BCCs are usually slow-growing and locally invasive which rarely metastasize.

Management of BCCs depend on whether these are low-risk or high risk tumours. Mohs micrographic surgery should be considered as gold standard treatment for high-risk BCCs. Other treatment options for BCCs include standard surgical excision, topical imiquimod or 5-fluorouracil, cryosurgery, curettage and cautery, photodynamic therapy and radiotherapy. Hedgehog pathway inhibitors may be considered for high-risk BCCs which are recurrent, incompletely excised or advanced.

SYMPOSIUM 11 - Dermato-Oncology

CLINICAL DECISION MAKING IN MALIGNANT MELANOMA: HOW TO TREAT IN 2025?**Linda Martin**

University of New South Wales and Melanoma Institute Australia, Australia

Melanoma management is rapidly evolving, with advances in non-invasive diagnostic modalities for early detection, and systemic therapies for advanced disease. A suite of risk estimation resources enable individualised care recommendations including personalised UV protection education, frequency of skin examination, indication for staging investigations and therapy choice. Shifts towards less invasive care of primary disease include non-invasive therapy for lentigo maligna and de-escalation of surgical margins. Neo-adjuvant immunotherapy is now standard of care for macroscopic stage III disease. Cutaneous toxicities from novel drug therapies pose a management challenge. Multidisciplinary care optimises outcomes, with supportive care required across all stages.

PRE-LUNCH SYMPOSIUM 5

TOCOTRIENOL-RICH MOISTURISER AND INFLAMED SKIN CONDITIONS**Lai Oi Ming**

Universiti Putra Malaysia, Selangor, Malaysia

Atopic dermatitis (AD) is a chronic skin condition often managed with corticosteroids, which pose long-term risks. Tocotrienol-rich fractions, known for antioxidant and anti-inflammatory properties, show potential as safer alternatives. Our research found that nanoencapsulated tocotrienols enhance skin barrier proteins, reduce inflammation, and promote healing in stressed skin cells. Preliminary clinical results in children with mild to moderate AD show reduced itchiness and improved skin health. These findings support further development of tocotrienol-based products as complementary options to improve quality of life in AD patients.

ORAL PRESENTATIONS

- ID 010 CUTANEOUS SARCOIDOSIS IN SINGAPORE: A 20-YEAR RETROSPECTIVE STUDY OF A MULTI-ETHNIC POPULATION**
Ong Kim Yao, Derek Lim Shi Yu, Chong Wei-Sheng
National Skin Centre, Singapore
- ID 011 EVALUATING SYPHILIS TREATMENT RESPONSE: AN 8-YEAR RETROSPECTIVE STUDY FROM HOSPITAL SULTAN ISMAIL, JOHOR BAHRU**
G P Chan, N Hithayathullah Khan, M J H Quek, L Selvarajah
Department of Dermatology, Hospital Sultan Ismail, Johor, Malaysia
- ID 048 EVALUATING THE IMPACT OF A PRE-RECORDED ONLINE VIDEO ON KNOWLEDGE, ATTITUDE AND PRACTICES OF DOCTORS TOWARDS SYPHILIS IN THE STATE OF TERENGGANU, MALAYSIA**
Loh Yoon Doong, Norazura Mohamad
Sultanah Nur Zahirah Hospital, Kuala Terengganu, Terengganu, Malaysia
- ID 055 RECALCITRANT DERMATOPHYTOSIS DUE TO TRICHOPHYTON INDOTINEAE: A CASE SERIES FROM SARAWAK, MALAYSIA**
Saifuddin S A S, Tan X T, Teo H G, Tang M M
Institute of Medical Research, Hospital Umum Sarawak, Sarawak, Malaysia
- ID 079 EFFICACY AND TOLERABILITY OF PIROCTONE OLAMINE, SACCHARIDE ISOMERATE AND HYDROXYPHENYL PROPAMIDOBENZOIC ACID CONTAINING FACE CREAM AS AN ADJUVANT FOR FACIAL DERMATITIS: A RANDOMIZED, DOUBLE-BLIND, PLA**
Ho Wen Chung
Universiti Putra Malaysia, Selangor, Malaysia
- ID 083 INFLUENCE OF GLYCEMIC CONTROL, DISEASE DURATION, AND PATIENT CHARACTERISTICS ON PRURITUS SEVERITY AMONG PATIENTS WITH DIABETES MELLITUS**
M Sundaran, W C Ho, K N How, N A Khabib, W Y Loh, A S Nanda, O C Ng
Universiti Putra Malaysia, Selangor, Malaysia
- ID 088 SAFETY ASSESSMENT OF CLINACANTHUS NUTANS CREAM IN HEALTHY VOLUNTEERS**
Heah Swee Kuan
Hospital Al-Sultan Abdullah, UiTM Puncak Alam, Selangor, Malaysia
- ID 095 CLINICAL AND LABORATORY CHARACTERISTICS OF TRICHOPHYTON INDOTINEAE INFECTION IN A NATIONAL TERTIARY DERMATOLOGY CENTRE**
Hui Xin See Tow^{1,2}, Cheryl Ann Ma Pei Wen^{1,2}, Norbariah Bte Mohd Shah^{1,2}, Kuan Ling Yee^{1,2}, Jiun Yit Pan^{1,2}
¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore
²National Skin Centre, Singapore
- ID 097 INDIRECT COST FOR PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS IN MALAYSIA: A MULTI-CENTRED STUDY**
Seah Xin Qian
Ministry of Health Malaysia
- ID 119 CLINICAL CHARACTERISTIC AND TREATMENT OUTCOME OF LIVEDOID VASCULOPATHY IN TERTIARY CARE HOSPITAL**
Nurul Izzah bt Aziz
Hospital Raja Permaisuri Bainun Ipoh, Perak, Malaysia

ORAL PRESENTATIONS

**ID 123 EFFICACY OF TUBERCULIN PURIFIED PROTEIN DERIVATIVE INJECTION AS
IMMUNOTHERAPY FOR THE TREATMENT OF RECALCITRANT CUTANEOUS WARTS:
A RETROSPECTIVE ANALYSIS IN A TERTIARY DERMATOLOGY CENTRE**

Wong Yee Fong, Ang Tick Sheng, Yew Kwang Meng, Tang Jyh Jong

Hospital Raja Permaisuri Bainun Ipoh, Perak, Malaysia

POSTER PRESENTATIONS

- ID 009 BEYOND THE BRUISE: A CASE OF FACIAL ANGIOSARCOMA PRESENTING MASQUERADING AS ECCHYMOSIS**
Brian Chia Keng Yong
Sengkang General Hospital, Singapore
- ID 012 EXAGGERATED INSECT BITE-LIKE REACTION ASSOCIATED WITH MANTLE CELL LYMPHOMA**
Norzana Binti Mohd Zakaria
Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
- ID 013 SCROTAL LYMPHANGIOMA CIRCUMSCRIPTUM IN A MIDDLE-AGED GENTLEMAN: A RARE CASE PRESENTATION**
L N Dong, L M Wayne, P Gunabalasingam, N A Tak
Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia
- ID 014 BEYOND THE BRUISE: A CASE OF FACIAL ANGIOSARCOMA MASQUERADING AS ECCHYMOSIS**
Brian Chia Keng Yong
Sengkang General Hospital, Singapore
- ID 015 CONTACT SENSITISATION IN MALAYSIA: A 5-YEAR SINGLE-CENTRE RETROSPECTIVE STUDY AND LITERATURE REVIEW**
Avril Long Ji Zi
Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
- ID 016 NETHERTON SYNDROME IN SARAWAK: A CASE SERIES**
Wei Xu Kong, Henrietta Albela
- ID 017 FAMILIAL SEBACEOUS HYPERPLASIA: A CASE SERIES AND THERAPEUTIC RESPONSE TO ORAL ISOTRETINOIN**
Noreen Binti Md Arus
Hospital Pakar Sultanah Fatimah, Muar, Johor, Malaysia
- ID 018 CUTANEOUS IMMUNE-RELATED ADVERSE EVENT FOLLOWING PEMBROLIZUMAB IN SMALL CELL LUNG CANCER: A CASE REPORT**
P W Ngo¹, P K Tu¹, I H Bakrin²
¹*Hospital Kulim, Kedah, Malaysia*
²*Universiti Putra Malaysia, Selangor, Malaysia*
- ID 019 MONKEYPOX HITS HOME! A VIRAL INTRUDER IN SARAWAK**
W S Tan, Saifuddin S A S, I P L Ting, H H Chua, M M Tang
Department of Dermatology, Sarawak General Hospital, Sarawak, Malaysia
- ID 020 SEXUALLY TRANSMITTED INFECTIONS: IS THERE A PATTERN CHANGE IN PATIENTS WHO ATTENDED THE GENITO-URINARY MEDICINE CLINIC, SARAWAK GENERAL HOSPITAL? A 15-MONTH SURVEY WITH THE ADDITIONAL MULTIPLEX RT-PCR**
S Y Foo, W S Tan, S M Ting, M M Tang
- ID 021 CLINICAL EFFICACY OF A MULTILAMELLAR CREAM ON SKIN PHYSIOLOGY AND MICROBIOME IN AN EPIDERMAL STRESS MODEL: A CONTROLLED DOUBLE-BLINDED STUDY (PART I)**
Tay Kuo Yuan
Martin Albrecht, gCt GmbH, Leichlingen, Germany

POSTER PRESENTATIONS

- ID 022 IMPACT OF MULTILAMELLAR FORMULATIONS ON STRATUM CORNEUM LIPID ORGANIZATION AND EPIDERMAL LIPID BARRIER ENHANCEMENT (PART II)**
Tay Kuo Yuan
Martin Albrecht, gCt GmbH, Leichlingen, Germany
- ID 023 CAREGIVER-RELATED FACTORS INFLUENCING TOPICAL CORTICOSTEROID ADHERENCE IN PEDIATRIC ATOPIC ECZEMA: A QUALITATIVE STUDY**
Elaine Liew Li Fong¹, Noraida Mohamed Shah¹, Munirah binti Ismail²
¹*Centre of Quality Management of Medicine, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia*
²*Clinical Research Center, Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia*
- ID 025 AN ATYPICAL CASE OF SYMMETRIC DRUG-RELATED INTERTRIGINOUS AND FLEXURAL EXANTHEMA (SDRIFE)**
Liang Yun Fei
Hospital Sultanah Nora Ismail, Batu Pahat, Johor, Malaysia
- ID 027 CUTANEOUS FALLOUT OF BENDAMUSTINE: A RARE PAPULOCRUSTED REACTION IN LEUKEMIA THERAPY - A CASE REPORT**
Aminuddin Bin Hasnol Aidi¹, Rasimah Binti Ismail², Asmah Hanim Binti Hamdan²
¹*Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia*
²*International Islamic University Malaysia, Kuantan, Pahang, Malaysia*
- ID 029 CLINICAL CHARACTERISTICS & OUTCOMES OF KAPOSIFORM HEMANGIOENDOTHELIOMA AND TUFTED ANGIOMA IN SARAWAK: A CASE SERIES**
Shalini Rajendran, Henrietta Albela
Sarawak General Hospital, Sarawak, Malaysia
- ID 030 A RARE CASE OF LYMPHANGIOMA CIRCUMSCRIPTUM IN AN ADULT – A CASE REPORT**
Ti Tiana¹, Nitiyah Anbalahan¹, Tan Wooi Chiang²
¹*Hospital Balik Pulau, Penang, Malaysia*
²*Hospital Pulau Pinang, Penang, Malaysia*
- ID 031 DRESS-SJS OVERLAP SYNDROME: A CASE REPORT**
Loh Chee Hoou
National Skin Centre, Singapore
- ID 033 TRIAL PROTOCOL FOR SIROSKIN: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF TOPICAL SIROLIMUS IN CHEMOPREVENTION OF FACIAL SQUAMOUS CELL CARCINOMAS IN SOLID ORGAN TRANSPLANT RECIPIENTS**
Natalie Teh
- ID 034 TUBEROUS SCLEROSIS IN PREGNANT LADY AND FETAL RHABDOMYOMA: A CASE REPORT**
Mohd Haniff Bin Abu Zarim
- ID 036 SYSTEMIC CONTACT DERMATITIS SECONDARY TO COBALT: A CASE REPORT**
C S Liong¹, Zakaria M F², T G Ng²
¹*Hospital Putrajaya, Putrajaya, Malaysia*
²*Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia*
- ID 037 LEPROMATOUS LYMPHADENITIS: A CASE REPORT**
Teo Sir Kit
Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia

POSTER PRESENTATIONS

- ID 038 APPLYING HEWÂ€™S FUNDAMENTAL HOMEOSTASIS THEORY IN ATTEMPT TO EXPLAIN THE CURE OF ALLERGY BY SACHA INCHI OIL NUTRITION**
Hew Nam Fong
ChM. Dr Hew Enterprise, Kuala Lumpur, Malaysia
- ID 039 SEVERE CUTANEOUS ADVERSE REACTIONS (SCARs): COMPARISON OF THE 5-YEAR TERENGGANU STATE LOCAL DATA TO THE MALAYSIAN NATIONWIDE DATA**
Loh Yoon Doong, Norazura Mohamad
Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia
- ID 040 ERYTHEMA ELEVATUM DIUTINUM; MIMICKING INFECTIOUS OR NEOPLASTIC SKIN LESION**
A N Azizan¹, R Che Ghani¹, N B Mohd Ismail¹, N S Fauzi¹, N F Yusof¹, N Mohamad¹, S Salehen¹, T N D Tengku Abu Bakar²
AN Azizan¹, R CheGhani¹, NB Mohd Ismail¹, NS Fauzi¹, NF Yusof¹, N Mohamad¹, S Salehen¹, TND Tengku Abu Bakar²
¹Department of Dermatology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia
²Department
- ID 041 A 5-YEAR RETROSPECTIVE CROSS-SECTIONAL STUDY ON DRUG SURVIVAL AND SAFETY PROFILE OF ACITRETIN FOR PSORIASIS IN TERTIARY SETTING, MALAYSIA**
Tan K K
Department of Pharmacy, Hospital Sultan Ismail, Johor, Malaysia
- ID 042 A DISTRICT HOSPITAL DIAGNOSTIC CHALLENGE: STEROID- INDUCED PUSTULAR ERUPTION POST ACUTE EXACERBATION BRONCHIAL ASTHMA Â€“ CANDIDIASIS, PSORIASIS OR BEYOND?**
Wong Jia Hui
Hospital Kuala Kubu Bharu, Selangor, Malaysia
- ID 043 ATYPICAL DRESS SYNDROME WITHOUT THE Â€œEÂ€: DIAGNOSTIC DILEMMA IN POLYMORBID PATIENT ON ANTI EPILEPTICS**
Wong Jia Hui
Hospital Kuala Kubu Bharu, Selangor, Malaysia
- ID 044 “WHEN FUNGI AND IMMUNITY COLLIDE: THE COMPLEX BATTLE OF SPOROTRICHOSIS IN AUTOIMMUNE HEPATITIS”: A CASE REPORT**
N S Fauzi¹, S Salehen¹, N F Yusof¹, NMohammad¹, N B Mohd Ismail¹, A N Azizan¹, S Hashim²
¹Department of Dermatology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia
²Department f Pathology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia
- ID 045 UNCOMMON BUT CRITICAL: A PAEDIATRIC CASE OF PEMPHIGUS VULGARIS**
Judhaimah Mardhiah
Department of Dermatology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia
- ID 046 A 7-YEARS RETROSPECTIVE STUDY ON NARROWBAND ULTRAVIOLET B (NBUVB) PHOTOTHERAPY UTILISATION EXPERIENCE IN A TERTIARY HOSPITAL IN KUANTAN, PAHANG**
Aminuddin Hasnol Aidi¹, Rasimah Ismail²
¹Universiti Kebangsaan Malaysia, Kuala Lumpur , Malaysia
²International Islamic University of Malaysia, Kuantan, Malaysia
- ID 049 WHAT COULD IT BE: HARD, PIGMENTED PLAQUES SIX YEARS AFTER AN ALLOGENIC HAEMATOPOEITIC STEM CELL TRANSPLANT**
Mah Tsing Yee
Hospital Umum Sarawak, Sarawak, Malaysia

POSTER PRESENTATIONS

- ID 050 PYODERMA GANGRENOSUM IN ASSOCIATION WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMEAR NEGATIVE PULMONARY TUBERCULOSIS: A CASE REPORT AT HOSPITAL BINTULU**
Lim Wei Hang
Hospital Bintulu, Sarawak, Malaysia
- ID 051 KIMURA AND HANSEN: A GENUINE ENCOUNTER OR A STRATEGIC MISDIRECTION?**
Lim Wei Hang
Hospital Bintulu, Sarawak, Malaysia
- ID 052 INVERTED FOLLICULAR KERATOSIS – A VARIANT OF SEBORRHEIC KERATOSIS?**
B H Ooi, R A Abdul Halim, H L Lee
Hospital Taiping, Perak, Malaysia
- ID 053 BULLOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT**
Saifuddin S A S^{1,2}, Chow Z H^{1,2}, Awang Basry N S^{1,2}, Zaharudin N S^{1,2}, Wan S A^{1,2}, Tang M M^{1,2}
¹*Hospital Umum Sarawak, Sarawak, Malaysia*
²*Hospital Bintulu Sarawak, Sarawak, Malaysia*
- ID 054 SEE BUT NOT PERCEIVED: AN OBLIVIOUS RACCOON EYES FOR NINE YEARS**
Haris N^{1,2}, Saifuddin S A S^{1,2}, Yahya B^{1,2}, Goh S^{1,2}, Zaharudin N S^{1,2}, Tang M M^{1,2}
¹*Hospital Umum Sarawak, Sarawak, Malaysia*
²*Hospital Bintulu Sarawak, Sarawak, Malaysia*
- ID 056 JAK INHIBITORS IN VITILIGO: THE SARAWAK GENERAL HOSPITAL EXPERIENCE**
Ingrid Pao Lin Ting¹, Sze Ying Foo², Hock Gin Teo³, Min Moon Tang²
¹*Dermatology Unit, Medical Department, Hospital Miri, Sarawak, Malaysia*
²*Department of Dermatology, Hospital Umum Sarawak, Sarawak, Malaysia*
- ID 062 THE SILENT BULGE: A CASE OF INDOLENT YET INVASIVE DERMATOFIBROSARCOMA PROTUBERANS**
Ingrid Pao Lin Ting¹, Azam Hilmi Mohd Zain², Min Moon Tang³
¹*Dermatology Unit, Medical Department, Hospital Miri, Sarawak, Malaysia*
²*Department of Pathology, Hospital Umum Sarawak, Sarawak, Malaysia*
- ID 078 WHEN THE SHIELD BACKFIRES: PARADOXICAL EMERGENCE OF CUTANEOUS SQUAMOUS CELL CARCINOMA WITH PEMBROLIZUMAB**
Khairunnisa Jailani, Nadiah Kamal Paramasivam, Nazatul Shima Abd Rahim
Hospital Putrajaya, Putrajaya, Malaysia
- ID 080 AN UNLIKELY CAUSE OF ECTHYMA GANGRENOSUM: COMMUNITY ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)**
B Sachdev, A F S M Zaini, A Jamil, N I Ismail
Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia
- ID 081 THE ANTIBIOTIC SUSCEPTIBILITY PATTERN OF NEISSERIA GONORRHOEAE ISOLATES IN SARAWAK GENERAL HOSPITAL: AN 11-YEAR RETROSPECTIVE REVIEW**
S Y Lim, Yan Teo, T H Lim, S M Ting, M M Tang
Hospital Umum Sarawak, Sarawak, Malaysia
- ID 082 BEYOND THE WOUND: A CASE REPORT OF DERMATITIS ARTEFACTA IN A FEMALE ADOLESCENT**
N Z X Ngu
Sibu Hospital, Sarawak, Malaysia

POSTER PRESENTATIONS

- ID 084 PATCH TEST RESULTS AND ALLERGEN TRENDS IN A MALAYSIAN HOSPITAL: A TWO-YEAR RETROSPECTIVE REVIEW**
Nur Hidayah Binti Abdul Hadi, Gary Chia Jian Qin
Department of Dermatology, Hospital Pakar Sultanah Fatimah, Muar, Johor, Malaysia
- ID 085 DETERMINING DIAGNOSTIC ACCURACY OF SKIN TEST, SPECIFIC IGE TEST AND PEN-FAST SCORE IN PENICILLIN ALLERGY PATIENTS**
Lai Siaw Ling
Hospital Umum Sarawak, Sarawak, Malaysia
- ID 086 PYODERMA GANGRENOsum: A REPORT OF THREE CASES AT HOSPITAL SIBU**
M A Suji¹, H G Teo², J Y Khaw¹, M M Tang³
¹*Department of Internal Medicine, Hospital Sibu, Sarawak, Malaysia*
²*Dermatology Unit, Hospital Sibu, Sarawak, Malaysia*
³*Department of Dermatology, Hospital Umum Sarawak, Sarawak, Malaysia*
- ID 087 BRIDGING IMMUNITY AND SAFETY: SUCCESSFUL GUSELKUMAB USE IN PSORIASIS WITH RESOLVED HEPATITIS C” A€“ A CASE REPORT**
S K Heah
Hospital Al-Sultan Abdullah, Universiti Teknologi MARA, Selangor, Malaysia
- ID 089 MORE THAN A RASH: A DIAGNOSTIC CHALLENGE IN ZINC DEFICIENCY**
Teo Yan
Kementerian Kesihatan Malaysia
- ID 090 REAL-WORLD SAFETY PROFILE OF JAK INHIBITORS IN ATOPIC DERMATITIS AND ALOPECIA AREATA: A RETROSPECTIVE OBSERVATIONAL STUDY**
Jean Nie Lim, Wooi Chiang Tan
Hospital Pulau Pinang, Penang, Malaysia
- ID 091 THE CLINICAL CHARACTERISTICS AND THERAPEUTIC OUTCOMES IN VITILIGO: A RETROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTER IN EAST MALAYSIA**
Ng Ling Fong
Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia
- ID 092 BRIDGING GAPS IN MALAYSIAN ACNE VULGARIS GUIDELINES: ADVISORY STATEMENTS ON TRIFAROTENE FOR FACIAL AND TRUNCAL ACNE**
How Kang Nien
Universiti Putra Malaysia, Selangor, Malaysia
- ID 093 EXPERT GROUP RECOMMENDATION ON THE ROLE AND CHOICE OF MOISTURIZERS IN ATOPIC DERMATITIS MANAGEMENT**
How Kang Nien
Universiti Putra Malaysia, Selangor, Malaysia
- ID 096 CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN LICHEN PLANUS: A MALAYSIAN SINGLE-CENTRE REVIEW**
Noreen Sharliza Naushad
Department of Dermatology, Penang General Hospital, Penang, Malaysia
- ID 102 ANIFROLUMAB FOR REFRACTORY CUTANEOUS LUPUS ERYTHEMATOSUS: A CASE REPORT DEMONSTRATING THERAPEUTIC POTENTIAL**
L N Dong, P Gunabalasingam
Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia

POSTER PRESENTATIONS

- ID 103 CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF CHRONIC HAND ECZEMA IN SKIN CLINIC, HOSPITAL PULAU PINANG**
Phang Lay Fang
Hospital Pulau Pinang, Penang, Malaysia
- ID 104 A RARE CASE OF ECTHYMA GANGRENOSUM CAUSED BY PROTEUS MIRABILIS INFECTION**
Liang Yun Fei
Sultanah Nora Ismail Hospital, Batu Pahat, Johor, Malaysia
- ID 105 DEMOGRAPHIC PROFILE, CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH LIP ECZEMA IN HOSPITAL PULAU PINANG**
Dalleen Leong Pei Chin
Hospital Pulau Pinang, Penang, Malaysia
- ID 107 GENERALIZED LICHEN AMYLOIDOSIS: A RARE PRESENTATION WITH EXTENSIVE CUTANEOUS INVOLVEMENT**
S F Goh, Preamala Gunabalasingam, Nor Akmar Tak
Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia
- ID 108 PRIMARY CUTANEOUS ASPERGILLOSIS CAUSED BY ASPERGILLUS TERREUS IN AN IMMUNOCOMPETENT WOMAN: A RARE CASE**
Mohd Arif Abdul Malik Khiew
Department of Dermatology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia
- ID 109 FATAL CASE OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA COMPLICATED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES**
Mohd Arif
Department of Dermatology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia
- ID 110 POST STEM CELL TRANSPLANT ZOSTERIFORM RASH: GRAFT-VERSUS-HOST DISEASE MASQUERADING AS HERPES ZOSTER**
B Sachdev, M Arumugam
Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
- ID 111 DIAGNOSTIC CONCORDANCE BETWEEN PRIMARY CARE PHYSICIANS AND DERMATOLOGISTS: A RETROSPECTIVE STUDY IN A TERTIARY HOSPITAL**
Ong Jee Seng, Abdul Rahman Che Abdul Rahim
Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
- ID 112 CLINICAL PATTERN OF INTERLEUKIN-23 (IL-23) INHIBITOR USE FOR PLAQUE PSORIASIS AT HOSPITAL AL-SULTAN ABDULLAH (HASA), UNIVERSITI TEKNOLOGI MARA, PUNCAK ALAM, MALAYSIA**
M S Shahrudin, Gan S H, S Ab Wahab, T Taib
- ID 113 DIVE DEEP INTO THE SKIN: LOBULAR PANNICULITIS AS A DIAGNOSTIC KEY TO MALAYSIA'S FIRST CASE OF LYME DISEASE**
Nur Izreena Ismail
Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
- ID 114 PATTERN OF REFERRALS TO PAEDIATRIC DERMATOLOGY CLINIC IN HOSPITAL RAJA PERMAISURI BAINUN IPOH**
Sia Rou, Ng Su Yuen, Pang Zhi Chiing
Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia

POSTER PRESENTATIONS

- ID 115 A 5-YEAR RETROSPECTIVE REVIEW OF PREVALENCE OF SKIN DISEASES IN DERMATOLOGY CLINIC, HOSPITAL KUALA LUMPUR**
Chin Hui Wenn, Priyya a/p Dato Subramaniam, Azura binti Mohd Affandi
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
- ID 116 A RETROSPECTIVE REVIEW OF METHOTREXATE USE IN SEVERE ATOPIC DERMATITIS AT PAEDIATRIC DERMATOLOGY CLINIC, HOSPITAL RAJA PERMAISURI BAINUN, IPOH**
Tan Sheng Chai
Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia
- ID 117 A RARE CASE OF PACHYONYCHIA CONGENITA**
Tan Sheng Chai, Deirdre Ooi
Hospital Wanita Dan Kanak-Kanak Sabah, Sabah, Malaysia
- ID 118 THE DUAL SWORD WARRIOR: BENRALIZUMAB IN ASTHMA AND ATOPIC ECZEMA**
Nur Izreena Ismail
Hospital Canselor Tuanku Muhriz UKM, Kuala Lumpur, Malaysia
- ID 120 KIMURA'S DISEASE OF NECK , A TUBERCULOUS LYMPHADENITIS MASQUARADE: A CASE REPORT**
Aravinthan a/l Balakrishnan
Hospital Kulim, Kedah, Malaysia
- ID 121 DIAGNOSTIC UTILITY OF INDIRECT IMMUNOFLOUORESCENCE IN AUTOIMMUNE BLISTERING DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY WITH CLINICOPATHOLOGICAL CORRELATION**
Hafsah Sazali, Syazwani Mohd Tajudin, Noor Suryani Mohd Ashari, Lim Jo Anne
- ID 122 THE UTILIZATION OF CUTANEOUS LASER TREATMENT IN DEPARTMENT OF DERMATOLOGY, HOSPITAL KUALA LUMPUR**
Wong Yee Fong, Wong Lok Chin, Azura Mohd Affandi
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
- ID 124 COMPARING THE EFFICACY AND TOLERABILITY OF OCTENIDINE AND CHLORHEXIDINE WASH IN ATOPIC DERMATITIS**
Y Y Kok, C S Lee
- ID 125 EVALUATION OF CLINICAL GUIDELINE ADHERENCE IN ORAL ISOTRETINOIN THERAPY AT PENANG HOSPITAL: A RETROSPECTIVE STUDY**
M W Kweh, W C Tan
Penang Hospital, Penang, Malaysia
- ID 126 CLINICAL RELEVANCE OF PATCH TESTING IN CHRONIC HAND AND FEET ECZEMA: EXPERIENCE FROM HOSPITAL KUALA LUMPUR**
W D Abdul Kadir, Y Y Kok, Y D Loh, A A Riduwan, A Mohd Affandi
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
- ID 127 WHEN ACID-FAST BACILLI MISLEAD: UNMASKING CUTANEOUS BARTONELLA IN A CHRONIC NODULAR DERMATOSIS**
Thubashini Marimuthu, Kanimoli Rathakrishnan
Hospital Sungai Buloh, Selangor, Malaysia

POSTER PRESENTATIONS

ID 128 PHOTOTHERAPY PRACTICE IN A TERTIARY DERMATOLOGY CENTRE: A 5-YEAR AUDIT IN HOSPITAL KUALA LUMPUR

Jassriwati Kosnin

Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

CLEANSE. MOISTURISE. OPTIMIZE ATOPIC DERMATITIS CARE

CLEANSE 1

Gently cleanses
without disrupting
the skin barrier




2 MOISTURISE

Restores and
maintains skin barrier



SKIN-IDENTICAL CERAMIDES*



Phytosphingosine-based ceramides (ceramides EOP, NP, & AP) play a key role in the organisation and strength of the skin barrier.¹

MULTIVESICULAR EMULSION (MVE) DELIVERY TECHNOLOGY



MVE Technology forms concentric layers of oil and water, capable of trapping both hydrophobic and hydrophilic ingredients.


*Ceramides EOP, NP, & AP are also referred to as ceramides 1, 3, & 6-II.

1. Kahraman E, Kaykin M, Bektay HS, Güngör S. Recent Advances on Topical Application of Ceramides to Restore Barrier Function of Skin. *Cosmetics*. 2019;6;52;doi:10.3390/cosmetics6030052




TRADE EXHIBITION

Connexion Conference & Event Centre @ Nexus, Level 3A



TRADE EXHIBITION

Nexus, Level 3A





BOOTH NO	COMPANY
F01	Neoasia (M) Sdn Bhd
F02	Bayer Co (Malaysia) Sdn Bhd
F03	JNTL (Kenvue)
F04	Kotra Pharma (M) Sdn Bhd
F05	Venusys Medical Sdn Bhd
F06	Schimdt Biomedtech Sdn Bhd
F07	Alliance Cosmetics Sdn Bhd
F08	V3Bio
F09 & F10	Novartis Corporation (M) Sdn Bhd
F11 & F12	Lipidgroup Sdn Bhd
F13	Rxillient Health
F14	Bio-Life Marketing
F15	MD Pharma
F16	Aenon Pharma
F17	Abbvie Sdn Bhd
F18	Mylan Healthcare Sdn Bhd
F19	Ego Pharm Malaysia Sdn Bhd
F20	Hoe Pharmaceuticals Sdn Bhd

BOOTH NO	COMPANY
F21	Germax Sdn Bhd
B01 & B02	Galderma (M) Sdn Bhd
B03 & B04	Sun Pharma (Ranbaxy)
B05 & B06	Glenmark Pharmaceuticals (M) Sdn Bhd
B07 & B08	Livemed Sdn Bhd
B09 & B10	Boehringer Ingelheim
B11 & B12	Johnson & Johnson Sdn Bhd
B13	Chuan Sin Sdn Bhd (Subsidiary of Spritzer Bhd)
B14 & B15	A. Menarini Singapore Pte Ltd
B16 & B17	Beiersdorf (Malaysia) Sdn Bhd
B18 & B19	DKSH-LEO Pharma
B20 & B21	Hyphens Pharma Sdn Bhd
B22 & B23	Sanofi-Aventis (Malaysia) Sdn Bhd
B24 & B25	Pfizer Malaysia Sdn Bhd
B26 & B27	GlaxoSmithKline (GSK) Pharmaceutical Sdn Bhd
B28 - B31	Loreal Dermatological Beauty
B32 - B35	Zuellig Pharma Sdn Bhd

TRADE EXHIBITION

Nexus, Level 3A



BOOTH NO	COMPANY
SP51	Blumo Biotech
SP52	innomed
SP56	Labceuticals

ACKNOWLEDGEMENTS

The Organising Committee of the 50th PDM Annual General Meeting & Annual Dermatology Conference 2025 would like to express its appreciation to the following for their support and contributions:

PLATINUM SPONSOR

L'ORÉAL

Dermatological Beauty

Loreal Dermatological Beauty

GOLD SPONSORS

GALDERMA

EST. 1981

Galderma (M) Sdn Bhd

GSK

GlaxoSmithKline (GSK)
Pharmaceutical Sdn Bhd



Pfizer Malaysia Sdn Bhd

sanofi

Sanofi-Aventis (Malaysia) Sdn Bhd

SILVER SPONSORS

 **MENARINI**
ASIA - PACIFIC

A. Menarini Singapore
Pte Ltd

Eucerin[®]

Beiersdorf (Malaysia)
Sdn Bhd

 **Boehringer
Ingelheim**

Boehringer Ingelheim


glenmark

A new way for a new world

Glenmark Pharmaceuticals
(M) Sdn Bhd

 **Hyphens**
Asean's Specialty Pharma Company

Hyphens Pharma Sdn Bhd

J&J

Johnson & Johnson Sdn Bhd



REMDII[®]

SENSITIVE

Lipidgroup Sdn Bhd

 **NOVARTIS**

Novartis Corporation (M) Sdn Bhd



SUN PHARMA

Sun Pharma (Ranbaxy)




ZUELLIG PHARMA

making healthcare more accessible

Zuellig Pharma Sdn Bhd

ACKNOWLEDGEMENTS

BRONZE SPONSORS



BRASS SPONSORS



CIBINQO
(abrocitinib) tablets 100mg
200mg

LESS ITCH.^{1*} LESS FLARE.^{1†}

MORE
LIFE.

When AD symptoms persist, help your patients get back to what they are missing. CIBINQO may provide:



Rapid and sustained disease control¹⁻⁴

Not an actual patient



A treatment designed for flexible dosing^{5,6}



Well-established long-term safety profile up to 4.5 years^{5,7-9}

CIBINQO is indicated for the treatment of patients 12 years of age and older with moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable.⁵

*CIBINQO 200 mg + topical therapy demonstrated superior itch relief 1 day after the first dose vs dupilumab + topical therapy, as measured by PP-NRS4.1 †CIBINQO 200 mg + topical therapy demonstrated skin clearance superiority to dupilumab + topical therapy at Week 4, as measured by EASI-90.¹ †Clinically meaningful improvements in DLQI were maintained through 48 weeks of treatment with CIBINQO 200 mg and 100 mg vs baseline in an ongoing long-term extension study.²

AD=atopic dermatitis; DLQI=Dermatology Life Quality Index; EASI-90=≥90% improvement in Eczema Area and Severity Index from baseline; PP-NRS4=≥4-point reduction from baseline on the Peak Pruritus Numerical Rating Scale.

References: 1. Reich K, et al. *Lancet*. 2022;400(10348):273–282. 2. Reich K, et al. *J Eur Acad Dermatol Venereol*. 2023;37(10):2047–2055. 3. Reich K, et al. *J Eur Acad Dermatol Venereol*. 2023;37(10):2056–2066. 4. Armstrong AW, et al. Poster presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference; April 9–11, 2022; Baltimore, Maryland, USA (Hybrid). 5. CIBINQO CLD Malaysia. 25 July 2025. 6. Blauvelt A, et al. *J Am Acad Dermatol*. 2023;86(1):104–112. 7. Supplement to: Simpson EL, et al. Poster presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress; May 31–June 3, 2024; Valencia, Spain. 8. Simpson EL, et al. Poster presented at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Meeting; May 31–June 3, 2024; Valencia, Spain. 9. Wollenberg A, et al. *J Eur Acad Dermatol Venereol*. 2023;37(10):2041–2046.



For Healthcare Professionals only
Pfizer Malaysia Sdn. Bhd. Registration No: 197801003134 (40131-T)
Level 10 & 11, Wisma Averis, Tower 2, Avenue 5, Bangsar South, No. 8,
Jalan Kerinchi, 59200 Kuala Lumpur.
Tel: 603-2281 6000 Fax: 603-2281 6388
www.pfizer.com.my
PP-CIB-MYS-0151-12AUG2025



Scan QR Code for CIBINQO
Full Prescribing Information

GALDERMA

EST. 1981

ADVANCING DERMATOLOGY FOR EVERY SKIN STORY



Restylane

**#1 DERMATOLOGICAL
SKINCARE BRAND***

**THE 1st TOPICAL ACNE TREATMENT
FOR THE FACE & TRUNK¹**

**24/7 456 DAYS
OF HEALTHY GLOW²**



Galderma Malaysia Sdn. Bhd. (Co. No: 201801029950 (1291976-D)) Unit 904, Level 9, Uptown One, Jalan SS21/58, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
***Source:** Based on internal analysis by Galderma Malaysia SDN BHD using data from the following source: IQVIA Malaysia National Sales Audit (NSA), sell-in sales units and values, total markets of ATC2 = D02 - EMOLLIENTS & PROTECTIVES category, for the period MAT Q4 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
References: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 2. Wu Y et al. J Cosmet Dermatol 2020;19(7):1627-1635. **Document No.:** MY-AFC-2400010 **Production Date:** Sept 2024 **FOR HEALTHCARE PROFESSIONAL USE ONLY.**